

MAR 1 0 2006 W

Sheet 1 of 39

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10177-191-999	10/603,115
APPLICANT	
Ding et al.	

GROUP

3738

## U.S. PATENT DOCUMENTS

FILING DATE

June 24, 2003

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATI
TB	A01	6,808,536	10/26/04	Wright, et al.			
	A02	6,783,543	08/31/04	Jang			
	A03	6,776,796	08/17/04	Falotico, et al.			
	A04	6,764,507	07/20/04	Shanley, et al.			
	A05	6,689,159	02/10/04	Lau, et al.			
	A06	6,663,881	12/16/03	Kunz, et al.			
	A07	6,656,216	12/02/03	Nossainy, et al.			
	A08	6,656,162	12/02/03	Santini Jr., et al.			
	A09	6,616,765	09/09/03	Castro, et al.			
	A10	6,616,690	09/09/03	Rolando, et al.			
	A11	6,599,928	07/29/03	Kunz, et al.			
	A12	6,596,022	07/22/03	Lau, et al.			
	A13	6,585,764	07/01/03	Wright, et al.			
	A14	6,575,993	07/10/03	Yock			
	A15	6,562,065	05/13/03	Shanley			
	A16	6,555,138	04/29/03	Karlsson			
	A17	6,544,790	04/08/03	Sabatini			
	A18	6,544,544	04/08/03	Hunter, et al.		}	
	A19	6,527,789	03/04/03	Lau, et al.			
	A20	6,515,009	02/04/03	Kunz, et al.			
	A21	6,497,647	12/24/02	Tucker			<del></del>
	A22	6,492,106	12/10/02	Sabatini et al.			
	A23	6,491,938	12/10/02	Kunz, et al.			<del></del>
	A24	6,491,617	12/10/02	Ogle, et al.			
	A25	6,488,694	12/03/02	Lau, et al.			
	A26	6,485,511	11/26/02	Lau, et al.			
	A27	6,476,200	11/05/02	Sabatini, et al.			
	A28	6,461,381	10/08/02	Israel, et al.			
	A29	6,443,982	09/03/02	Israel, et al.			
	A30	6,432,133	08/13/02	Lau, et al.			
	A31	6,429,232	08/06/02	Kinsella, et al.			
	A32	6,395,326	05/28/02	Castro, et al.		1	
	A33	6,358,989	03/19/02	Kunz, et al.			
	A34	6,309,414	10/30/01	Rolando, et al.			
-	A35	6,309,412	10/30/01	Lau, et al.			· · · · · · · · · · · · · · · · · · ·

	<del></del>	1-7-2-2-3-3-3-3-3-3-3-3-3-3-3-3-3-3-3-3-3	1	<del></del>	 on No. 10/603,115
TB	A36	6,306,421	10/23/01	Kunz, et al.	
	A37	6,273,913	08/14/01	Wright, et al.	
	A38	6,268,390	07/31/01	Kunz	
<u> </u>	A39	6,251,920	06/26/01	Grainger, et al.	
	A40	6,241,762	06/05/01	Shanley	
	A41	6,210,393	04/03/01	Brisken, et al.	
	A42	6,203,536	03/20/01	Berg, et al.	
	A43	6,187,370	02/13/01	Dinh, et al.	
	A44	6,171,609	01/09/01	Kunz	
	A45	6,168,619	01/02/01	Dinh, et al.	
	A46	6,152,869	11/28/00	Park, et al.	
	A47	6,146,358	11/14/00	Rowe	
	A48	6,133,242	10/17/00	Zalewski, et al.	
	A49	6,129,757	10/10/00	Weadock	
	A50	6,106,454	08/22/00	Berg, et al.	
	A51	6,120,536	09/19/00	Ding, et al.	
	A52	6,099,562	08/08/00	Ding, et al.	
	A53	6,099,499	08/08/00	Ciamacco, et al.	
	A54	6,093,142	07/25/00	Kunz, et al.	
	A55	6,087,479	07/11/00	Stamler, et al.	
	A56	6,086,910	07/11/00	Howard, et al.	
	A57	6,074,659	06/13/00	Kunz, et al.	
	A58	6,074,337	06/13/00	Tucker et al.	
	A59	6,066,167	05/23/00	Lau, et al.	
	A60	6,036,715	03/14/00	Yock	
	A61	6,033,866	02/08/00	Falk, et al.	
	A62	6,013,099	01/11/00	Dinh, et al.	
	A63	6,001,622	12/14/99	Dedhar, et al.	
	A64	5,990,095	11/23/99	Falk, et al.	
	A65	5,981,568	11/09/99	Kunz, et al.	
	A66	5,972,018	10/26/99	Israel, et al.	
	A67	5,948,639	09/07/99	Ginemo, et al.	
	A68	5,945,456	08/31/99	Grainger, et al.	
	A69	5,902,332	05/11/99	Schatz	
	A70	5,873,904	02/23/99	Ragheb, et al.	
	A71	5,863,285	01/26/99	Coletti	
	A72	5,847,007	12/08/98	Grainger, et al.	
	A73	5,843,120	12/01/98	Israel, et al.	
	A74	5,837,313	11/17/98	Ding, et al.	
	A75	5,837,008	11/17/98	Berg, et al.	
	A76	5,824,647	10/20/98	Postlethwaite, et al.	
	A77	5,824,049	10/20/98	Ragheb, et al.	
	A78	5,821,234	10/13/98	Dzau	
	A79	5,811,447	09/22/98	Kunz, et al.	
	A80	5,797,898	08/25/98	Santini Jr., et al.	

			<del></del>	· · · · · · · · · · · · · · · · · · ·	of Applic	ation No. 10/603,115
TB	A81	5,773,479	06/30/98	Grainger, et al.		
	A82	5,770,609	06/23/98	Grainger, et al.		
	A83	5,767,079	06/16/98	Glaser, et al.		
	A84	5,749,888	05/12/98	Yock		
	A85	5,747,510	05/05/98	Draper		
	A86	5,733,925	03/31/98	Kunz, et al.		
	A87	5,733,303	03/31/98	Israel, et al.		
	A88	5,731,424	03/24/98	Toothman, et al.		
	A89	5,731,200	03/24/98	Ichijo, et al.		
	A90	5,731,144	03/24/98	Toothman, et al.		
	A91	5,726,186	03/10/98	Grese		
	A92	5,705,609	01/06/98	Ruoslahti, et al.		
	A93	5,705,477	01/06/98	Sporn, et al.		
	A94	5,693,607	12/02/97	Segrini, et al.		
	A95	5,688,813	11/18/97	Sall, et al.		
	A96	5,686,476	11/11/97	May		
	A97	5,686,467	11/11/97	Bumol, et al.		
-	A98	5,681,835	10/28/97	Willson		
	A99	5,677,295	10/14/97	Failli, et al.		
	A100	5,667,764	09/16/97	Kopia, et al.		
	A101	5,665,728	09/09/97	Morris, et al.		
	A102	5,660,873	08/26/97	Nikolaychik, et al.		
	A103	5,658,951	08/19/97	Magarian, et al.		
	A104	5,658,927	08/19/97	Magarian, et al.		
	A105	5,658,883	08/19/97	Ogawa, et al.		
	A106	5,656,587	08/12/97	Sporn, et al.		
	A107	5,656,450	08/12/97	Boyan, et al.		
	A108	5,652,259	07/29/97	May		
	A109	5,651,627	07/29/97	Dowzall, et al.		
	A110	5,646,160	07/08/97	Morris, et al.		
		5,641,790	06/24/97	Draper		
		5,639,738	06/17/97	Falk, et al.		
		5,639,274	06/17/97	Fischell, et al.	•	
		5,635,489	06/03/97	Haley		
		5,626,600	05/06/97	Horzewski, et al.		
		5,622,975	04/22/97	Singh, et al.		
		5,616,608	04/01/97	Kinsella, et al.		
		5,610,168	03/11/97	Draper		
		5,610,166	03/11/97	Singh		
		5,609,629	03/11/97	Fearnot, et al.		
		5,605,700	02/25/97	DeGregorio, et al.		
		5,599,844	02/04/97	Grainger, et al.		
		5,599,352	02/04/97	Dinh, et al.	_	
		5,597,578	01/28/97	Brown, et al.		
$-\Psi$		5,595,722	11/21/97	Grainger, et al.		

r		T			·	of Application	140. 10/003,113
TB		5,583,153	12/10/96	Brahn			
		5,580,898	12/03/96	Trojanowski, et al.			
		5,578,703	11/16/96	Ichijo, et al.			
		5,576,345	11/19/96	Mansson, et al.			
	A130	5,574,047	11/12/96	Bumol, et al.			
	A131	5,571,808	11/05/96	Leeds			
	A132	5,571,714	11/05/96	Dasch, et al.			
	A133	5,571,166	11/05/96	Dinh, et al.			
	A134	5,567,713	10/22/96	Cullinan, et al.			
	A135	5,563,146	10/08/96	Morris, et al.			
	A136	5,563,145	10/08/96	Failli, et al.			
	A137	5,563,054	10/08/96	Briggs, et al.			
	A138	5,562,922	10/08/96	Lambert			
	A139	5,556,876	09/17/96	Bryant, et al.			
	A140	5,554,182	09/10/96	Dinh, et al.			
	A141	5,552,433	09/03/96	Bryant, et al.			-
	A142	5,552,415	09/03/96	May			
	A143	5,545,569	08/13/96	Grainger, et al.			
	A144	5,545,409	08/13/96	Laurencin, et al.			
	A145	5,541,174	07/30/96	Sorenson			
	A146	5,538,892	06/23/96	Donahoe, et al.			
	A147	5,534,527	07/09/96	Black, et al.			
	A148	5,527,337	06/18/96	Stack, et al.			······································
	A149	5,525,624	06/11/96	Gitter, et al.			
	A150	5,525,610	06/11/96	Caufield, et al.			
	A151	5,521,198	05/28/96	Zuckerman			
	A152	5,521,191	05/28/96	Greenwald			
	A153	5,521,172	05/28/96	Bryant, et al.			
	A154	5,521,171	05/28/96	Sorenson			
	A155	5,519,042	05/21/96	Morris, et al.			
	A156	5,516,807	05/14/96	Hupe, et al.			
		5,516,781	05/14/96	Morris, et al.			
	A158	5,514,154	05/07/96	Lau, et al.			
	A159	5,512,268	04/30/96	Grinstaff, et al.			
	A160	5,510,370	04/23/96	Hock, et al.			<del>/</del>
1	A161	5,508,292	04/16/96	Sall, et al.			
	A162	5,504,091	04/02/96	Molnar-Kimber, et al.			
	A163	5,498,775	03/12/96	Novak, et al.		<u> </u>	<del></del>
	A164	5,496,851	03/05/96	Grinnell			<del> </del>
	A165	5,496,828	03/05/96	Cullinan	-		
	A166	5,496,581	03/05/96	Yianni, et al.			
<b>-</b>		5,496,346	03/05/96	Horzewski, et al.			
	A168	5,492,927	02/20/96	Gitter, et al.		<b></b>	
		5,492,926	02/20/96	Cullinan, et al.			
V		5,492,922	02/20/96	Palkowitz			

							of Application	on No. 10/603,115
TB	A	171	5,492,921	02/20/96	Bryant, et al.			
	A	172	5,491,173	02/13/96	Toivola, et al.			
	A	173	5,491,159	02/13/96	Malamas			
	A	74	5,489,587	02/06/96	Fontana		Ì	
	A	175	5,484,808	01/16/96	Grinell			
	A	76	5,484,798	01/16/96	Bryant, et al.	· · · · · · · · · · · · · · · · · · ·		
	A	77	5,484,797	01/16/96	Bryant, et al.			
	A	78	5,484,796	01/16/96	Bryant, et al.			
	A	79	5,484,795	01/16/96	Bryant, et al.			
	A	80	5,482,950	01/09/96	Bryant, et al.			
	A	81	5,482,949	01/09/96	Black, et al.			
	A	82	5,482,851	01/09/96	Derynck, et al.			
	A	83	5,480,904	01/02/96	Bryant, et al.			7
	A	84	5,480,903	01/02/96	Piggott, et al.			
	A	85	5,480,888	01/02/96	Kodama, et al.			
	A	86	5,478,860	12/26/95	Wheeler, et al.			
	A	87	5,478,847	12/26/95	Draper			
	A	88	5,472,985	12/05/95	Grainger, et al.			
	A	89	5,470,883	11/28/95	Stromberg			
	A	90	5,470,876	11/28/95	Proctor			
	A	91	5,468,746	11/21/95	Casagrande, et al.			
	A	92	5,466,810	11/14/95	Godfrey			
	Al	93	5,464,450	11/07/95	Buscemi, et al.			
	A	94	5,462,966	10/31/95	Sofia			
	A	95	5,462,950	10/31/95	Fontana	*****		
	Al	96	5,462,949	10/31/95	Jones, et al.			
	Al	97	5,462,937	10/31/95	Cullinan, et al.			
	Al	98	5,462,925	10/31/95	Ogawa, et al.			
	Al	99	5,461,065	10/24/95	Black, et al.			
	A2	00	5,461,064	10/24/95	Cullinan, G.J.			
	A2	01	5,460,807	10/24/95	Cardin, et al.			
	A2	02	5,458,568	10/17/95	Racchini, et al.			
	A2	03	5,457,117	10/10/95	Black, et al.			
	Λ2	04	5,457,116	10/10/95	Black, et al.			
	A2	05	5,457,113	10/10/95	Cullinan, et al.		1	
	A2	06	5,455,275	10/03/95	Fontana			
	A2	07	5,453,492	09/26/95	Butzow, et al.			
	A2	08	5,453,442	09/26/95	Bryant, et al.			
	A2	09	5,453,436	09/26/95	Ohlstein			
	A2	10	5,451,603	09/19/95	Piggott			
	A2	11	5,451,590	09/19/95	Dodge			
	A2	12	5,451,589	09/19/95	Dodge			
	A2	13	5,451,414	09/19/95	Steward			
	A2	14	5,451,233	09/19/95	Yock	<del></del>		
V	A2	15	5,447,941	09/05/95	Zuckerman			

<del></del>			· · · · · · · · · · · · · · · · · · ·		0	i Applicatio	n No. 10/603,115
TB	A216	5,446,070	08/29/95	Mantelle			
		5,446,053	08/29/95	Keohane			
		5,445,941	08/29/95	Yang			
	A219	5,444,164	08/22/95	Purchio, et al.			
	A220	5,443,458	08/22/95	Eury			
	A221	5,441,986	08/15/95	Thompson			
	A222	5,441,966	08/15/95	Dodge			
	A223	5,441,965	08/15/95	Sall, et al.			
	A224	5,441,964	08/15/95	Bryant, et al.			
	A225	5,441,947	08/15/95	Dodge, et al.			
	A226	5,441,734	08/15/95	Reichert, et al.			
	A227	5,439,931	08/08/95	Sales			<del></del>
	A228	5,439,923	08/08/95	Cullinan			
	A229	5,439,689	08/08/95	Hendrickson, et al.			
	A230	5,436,243	07/25/95	Sachs, et al.			
	A231	5,434,166	07/18/95	Glasebrook			
	A232	5,429,634	07/04/95	Narcisco, et al.			
	A233	5,426,123	06/20/95	Fontana			
	A234	5,424,331	06/13/95	Shlyankevich			
	A235	5,423,885	06/13/95	Williams			
	A236	5,422,362	06/06/95	Vincent, et al.			"
	A237	5,421,955	06/06/95	Lau, et al.			
	A238	5,420,243	05/30/95	Ogawa, et al.			
	A239	5,418,252	05/23/95	Williams			
	A240	5,416,205	05/16/95	Della Valle, et al.		•	
	A241	5,411,988	05/02/95	Bockow, et al.			
	A242	5,411,967	05/02/95	Kao, et al.			
	A243	5,407,658	04/18/95	Hattner			
	A244	5,407,609	04/18/95	Tice, et al.			
	A245	5,401,730	03/28/95	Sauvage, et al.			
	A246	5,395,842	03/07/95	Labrie, et al.			
		5,395,610	03/07/95	King			
	A248	5,393,785	02/28/95	Labrie, et al.			
	A249	5,393,772	02/28/95	Yu, et al.			
	A250	5,393,763	02/28/95	Black, et al.			
	A251	5,391,557	02/21/95	Cullinan, et al.			
	A252	5,389,670	02/14/95	Fontana			
	A253	5,387,680	02/07/95	Nelson	- "		
	A254	5,385,935	01/31/95	Tamai, et al.			
	A255	5,384,332	01/24/95	Fontana			
	A256	5,380,716	01/10/95	Conrad, et al.			
		5,364,843	11/15/94	King,			
	A258	5,364,632	11/15/94	Benita			
		5,362,718	11/08/94	Skotnicki, et al.		· · · · · · · · · · · · · · · · · · ·	
V		5,362,478	11/08/94	Desai, et al.			

					of Application	
TB	A261	5,362,424	11/08/94	Lee, et al.		
1	A262	5,358,844	10/25/94	Stossel, et al.		
	A263	5,356,713	10/18/94	Charmot, et al.		
	A264	5,354,801	10/11/94	O'toole, et al.		
	A265	5,354,774	10/11/94	Deckelbaum, et al.		
	A266	5,354,562	10/11/94	Platz, et al.		
	A267	5,346,993	09/13/94	Miyazono, et al.		
	A268	5,346,897	09/13/94	King		
	A269	5,346,702	09/13/94	Na, et al.		
	A270	5,344,926	09/13/94	Murakata, et al.		
	A271	5,342,926	08/30/94	Hattner		
	A272	5,340,925	08/23/94	Lioubin, et al.		
	A273	5,332,584	07/26/94	Scher, et al.		
	A274	5,332,576	07/26/94	Mantelle		
	A275	5,328,471	07/12/94	Slepian		
	A276	5,326,757	07/05/94	Demopoulos		
	A277	5,324,739	06/28/94	Germick, et al.		-
	<del></del>	5,324,736	06/08/94	Magarin, et al.		
		5,316,766	05/31/94	Baldus, et al.		
	A280	5,314,679	05/24/94	Lewis, et al.		
	A281	5,308,862	05/03/94	Ohlstein, et al.		·····
	A282	5,308,622	05/03/94	Casscells, et al.		
	A283	5,304,541	04/19/94	Purchio, et al.		
	A284	5,304,325	04/19/94	Kaufman, et al.		
	<del></del>	5,302,584	04/12/94	Kao, et al.		
	A286	5,296,492	03/22/94	Shiozawa et al.		
	I I	5,290,271	03/01/94	Jernberg		
	A288	5,288,735	02/22/94	Trager, et al.		
		5,284,869	02/08/94	Bisaccia, et al.		
		5,284,763	02/08/94	Derynk, et al.		
		5,283,257	02/01/94	Gregory, et al.		
		5,282,785	02/01/94	Shapland, et al.		
	A293		01/18/94	Miyazono et al.		
	A294	· · · · · · · · · · · · · · · · · · ·	01/18/94	Labroo, et al.		
		5,280,016	01/18/94	Conrad, et al.		
		5,270,047	12/14/93	Kauffman, et al.		
		5,268,455	12/07/93	Cianciolo		······································
	A298	5,268,358	12/07/93	Fretto, et al.		
		5,262,319	11/16/93	Iwata, et al.		
		5,260,224	11/09/93	Stossel, et al.		
	A301	5,254,594	10/19/93	Niikura, et al.		
	A302		10/12/93	Skotnicki, et al.		
	A303	5,248,764	09/28/93	Flanagan, et al.		
	A304	5,242,397	09/07/93	Barath, et al.		
$ \forall$		5,238,950	08/24/93	Clader, et al.		

					or Application	1140. 10/003,113
TB	A306	5,238,714	08/24/93	Wallace, et al.		
1	A307	5,234,957	08/10/93	Mantelle		
	A308	5,234,456	08/10/93	Silverstrini		
	A309	5,232,911	08/03/93	Vidal, et al.		
	A310	5,232,444	08/03/93	Just, et al.		
	A311	5,229,495	07/20/93	Ichijo, et al.		
	A312	5,226,430	07/13/93	Spears, et al.		
	A313	5,221,620	06/22/93	Purchio, et al.		
	A314	5,219,548	06/15/93	Yang, et al.		
	A315	5,216,126	06/01/93	Cox, et al.		
	A316	5,216,024	06/01/93	Markaverich, et al.		
	A317	5,216,021	06/01/93	Sorenson		
	A318	5,213,580	05/25/93	Slepian, et al.		
	A319	5,213,576	05/25/93	Abiuso, et al.		
	A320	5,211,940	05/18/93	Ishiguro, et al.		
	A321	5,208,238	05/04/93	King		
	A322	5,208,019	05/05/93	Hanson, et al.		
	A323	5,199,939	04/06/93	Dake, et al.		
	A324	5,195,984	03/23/93	Schatz		
	A325	5,192,525	03/09/93	Yang, et al.		
	A326	5,189,212	02/23/93	Ruenitz		
	A327	5,189,046	02/23/93	Burch, et al.		
	A328	5,185,260	02/09/93	Crissman, et al.		
	A329	5,176,617	01/05/93	Fischell, et al.		
	A330	5,175,235	12/29/92	Domb, et al.		
	A331	5,171,217	12/15/92	March, et al.		-
	A332	5,167,960	12/01/92	Ito, et al.		
	A333	5,166,191	11/24/92	Cronin, et al.		
	A334	5,166,143	11/24/92	Ondetti, et al.		
	A335	5,145,838	09/08/92	Pickart		-
	A336	5,145,684	09/08/92	Liversidge, et al.		
		5,140,012	08/18/92	McGovern, et al.		,
	A338	5,126,348	06/30/92	МсМиттау.		
	A339	5,120,535	06/09/92	Marguardt, et al.		
	A340	5,118,791	06/02/92	Burnier, et al.		
	A341	5,116,864	05/26/92	March, et al.		
	A342	5,114,847	05/19/92	Jungfer, et al.		
	A343	5,114,719	05/19/92	Sabel, et al.		
	A344	5,112,305	05/12/92	Barath, et al.		
	A345	5,108,989	05/28/32	Amento, et al.		
	A346		04/07/92	Dror, et al.		
		5,100,885	03/31/92	Abrams, et al.		
		5,099,504	03/24/92	Pettit		
<u> </u> .	A349	5,098,903	03/24/92	Magarian, et al.		
$-\Lambda$		5,093,330	03/03/92	Caravatti, et al.		

					 ot Applicatio	n No. 10/603,115
TB	A351	5,082,834	01/21/92	Sorenson		
	A352	5,075,321	12/24/91	Schreiber		
	A353	5,073,633	12/17/91	Schroeder, et al.		
	A354	5,066,789	11/19/91	Srinivasa, et al.		
	A355	5,061,273	10/29/91	Yock		
	A356	5,053,033	10/01/91	Clarke, et al.		
	A357	5,049,132	09/17/91	Schaffer, et al.		
	A358	5,047,431	09/10/91	Schickaneder, et al.		
	A359	5,043,335	08/27/91	Kleinschroth, et al.		
	A360	5,040,548	08/20/91	Yock		
	A361	5,037,641	08/06/91	Juhos, et al.		
	A362	5,032,679	07/16/91	Brandley, et al.		~
	A363	5,030,637	07/09/91	Einzig, et al.		
	A364	5,026,537	06/25/91	Daddona, et al.		
	A365	5,023,237	06/11/91	Pickart, et al.		
	A366	5,019,504	05/28/91	Christen, et al.	 	
	A367	5,015,666	05/14/91	Magarian, et al.		
	A368	5,015,578	05/14/91	Schroeder, et al.		
	A369	5,009,659	04/23/91	Hamlin		
	A370	5,008,279	04/16/91	Franckowiak, et al.		
	A371	5,002,531	03/26/91	Bonzel		
	A372	4,999,347	03/12/91	Sorenson		
	A373	4,997,652	03/05/91	Wong		
	A374	4,996,225	02/26/91	Toivola, et al.		
.	A375	4,994,384	02/19/91	Prather, et al.		
	A376	4,994,033	02/19/91	Shockey, et al.	 	
	A377	4,990,538	02/05/91	Harris, et al.		
	A378	4,984,594	01/15/91	Vinegar, et al.		
	A379	4,973,755	11/27/90	Gafe, et al.		
	A380	4,973,601	11/27/90	Dowd, et al.		
	A381	4,968,350	11/06/90	Bindschaedler, et al.		
	A382	10000	10/09/90	Eppstein et al.		
	A383	4,959,355	09/25/90	Fischbarg, et al.		
1	A384	4,956,188	09/11/90	Anderson	·	
		4,952,607	08/28/90	Sorenson		
		4,935,415	06/19/90	Nakane, et al.		
	A387	4,929,602	05/29/90	Harker, et al.		•
	A388	4,906,452	03/06/90	Sivam, G		
	A389	4,900,561	02/13/90	Abdel-Monem, et al.		
	A390	4,897,255	01/30/90	Fritzberg, et al.		
	A391	4,879,315	11/07/89	Magarian, et al.		
	A392	4,879,225	11/07/89	Morgan Jr., et al.	-	<u> </u>
	A393	4,867,973	09/19/89	Goers, et al.	·	
<u> </u>	A394		08/22/89	Sonnenschein, et al.		
<del></del>	A395	4,853,377	08/01/89	Pollack,	 	

					of Applicatio	n No. 10/603,115
TB	A396	4,840,939	06/20/89	Leveen, et al.		
	A397	4,839,155	06/13/89	McCague		
	A398	4,835,002	05/30/89	Wolf, et al.		
	A399	4,826,672	05/02/89	Milius, et al.		
	A400	4,824,661	04/25/89	Wagner		
	A401	4,824,436	04/25/89	Wolinsky	 •	
	A402	4,793,348	12/27/88	Palmaz		
	A403	4,767,758	08/30/88	Breccia, et al.		
	A404	4,762,129	08/09/88	Bonzel		
	A405	4,760,051	07/26/88	Pickart		
	A406	4,758,555	07/19/88	Sorenson		
	A407	4,758,554	07/19/88	Sorenson, et al.	-	
	A408	4,757,059	07/12/88	Sorenson		
	A409	4,748,982	06/07/88	Horzewski, et al.		
	A410	4,744,981	05/17/88	Pavanasasivam		
	A411	4,733,665	03/29/88	Palmaz		
	A412	4,732,763	03/22/88	Beck, et al.		
	A413	4,705,647	11/10/87	Yamaguchi, et al.		
	A414	4,696,949	08/29/87	Toivola, et al.		
	A415	4,675,189	06/23/87	Kent, et al.		
	A416	4,670,428	06/02/87	Sorenson		
	A417	4,664,097	05/12/87	McGrath, et al.		
	A418	4,657,928	04/14/87	Sorenson		
	A419	4,629,694	12/16/86	Harpel		
	A420	4,605,644	08/12/86	Foker		
	A421	4,577,636	03/25/86	Spears		
	A422	4,555,402	11/26/85	Matsuda, et al.		
	A423	4,536,516	08/20/85	Harper, et al.		
	A424	4,512,762	04/23/85	Spears		
	A425	4,491,574	01/01/85	Seifter, et al.		
	A426	4,487,780	12/11/84	Scheinberg		
	A427	4,485,097	11/27/84	Bell		
	A428	4,485,096	11/27/84	Bell		
	A429	4,442,119	04/10/84	Magarian, et al.		
	A430	4,440,754	04/03/84	Sorenson		
	A431	4,428,963	01/31/84	Confalone, et al.		
	A432	4,418,068	11/29/83	Jones		
	A433	4,389,330	06/21/83	Tice, et al.		
	A434	4,382,143	05/03/83	Shepherd		
	A435	4,380,635	04/19/83	Peters		
	A436	4,339,429	07/13/82	Raaf, et al.		
	A437	4,332,791	06/01/82	Raaf, et al.		
	A438	4,323,707	04/06/82	Suarez, et al.		
	A439	4,317,915	03/02/82	Confalone, et al.		
W	A440	4,315,028	02/09/82	Scheinberg		

						 1 / ippiicalio	n No. 10/603,115
TB		A441	4,310,523	01/12/82	Neumann		
		A442	4,307,111	12/22/81	Crawley		
		A443	4,287,190	09/01/81	Boettcher, et al.		
		A444	4,282,246	08/04/81	Holland		
		A445	4,239,778	12/16/80	Venton, et al.		
		A446	4,235,988	11/25/80	Fildes, et al.		
		A447	4,230,862	10/28/80	Suarez, et al.		
		A448	4,221,785	09/09/80	Sorenson		
	$\Pi$	A449	4,219,656	08/26/80	Press, et al.		
		A450	4,205,685	06/03/80	Yoshida, et al.		
		A451	4,133,814	01/09/79	Jones, et al.		
		A452	4,093,709	06/06/78	Sok, et al.		
	П	A453	4,070,484	01/24/78	Harita, et al.		
	П	A454	3,940,422	02/24/76	Harita, et al.		
		A455	3,634,517	01/11/72	Palopoli, et al.		
		A456	3,445,473	05/20/69	Ruschig, et al.		
		A457	3,288,806	11/29/66	Dewald, et al.		
		A458	3,168,565	02/02/65	Palopoli, et al.		
		A459	3,010,965	11/28/61	Elpern		
		A460	2,914,563	11/24/59	Allen, et al.		
		A461	RE 33,403	11/23/90	Stolle, et al.		
		A462	RE 32,944	06/06/89	K. Harita, et al.		
	*	A463	2004/0236416	11/25/04	Falotico		
		A464	2003/0039675	02/27/03	Kunz, et al.		
		A465	2002/0086896	07/04/02	Kunz, et al.		
		A466	2002/0040064	04/04/02	Kunz, et al.		
		A467	2002/0013275	01/31/02	Kunz, et al.		
		A468	2002/0032477	03/14/02	Helmus, et al.		
V		A469	2002/0091433	07/11/02	Ding, et al.		

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ΤA、
							YES	Γ
TB	B01	31079/93	07/15/93	Australian Patent Application				
	B02	09-255570	03/21/96	Japan				Γ
	B03	59-042375	03/08/84	Japan				T
	B04	60-25288	02/01/94	Japan				T
	B05	32-97469	12/27/91	Japan				T
	B06	1 015 787	01/05/96	United Kingdom				T
	B07	1 587 084	05/25/81	United Kingdom			İ	T
	B08	2 273 873	06/07/94	United Kingdom				T
	B09	2,231,727	09/14/04	Canada			<u> </u>	T
	B10	2,079,205	03/26/94	Canada				T
	B11	2,086,642	07/10/93	Canada				T
V	B12	2255063	07/18/75	France	<del>-  </del>			T

				,			of Application	110. 10/002	,,,,
TB	L	B13	4320896	01/05/95	Germany				
		B14	4320898	01/05/95	Germany				Γ
		B15	4401554	08/18/94	Germany				
		B16	1247527	04/24/91	Italy				
		B17	EP 0 095 875 A2	12/07/83	Europe				T
		B18	EP 0 002 341	06/13/79	Europe				<del>                                     </del>
		B19	EP 0 024 096	02/25/81	Europe	····	<del></del>		
	$T^{-}$	B20	EP 0 054 168 A1	06/23/82	Europe	<del></del>			T
		B21	EP 0 260 066 B1	03/16/88	Europe				
	T	B22	EP 0 297 946	01/04/89	Europe		<del></del>	<del></del> -	
	<del>                                     </del>	B23	EP 0 365 863 B1	05/02/90	Europe		· · · · · · · · · · · · · · · · · · ·		✝
	1	B24	EP 0 374 044 B1	06/20/90	Europe				T
		B25	EP 0 411 893	02/06/91	Europe				⇈
$\neg$	<u> </u>	B26	EP 0 451 202 B1	10/16/91	Europe				╁
	T	B27	EP 0 524 093	01/20/93	Europe			<b></b>	╁
	T	B28	EP 0 526 102	02/03/93	Europe			<u> </u>	╁╴
	$\vdash$	B29	EP 0 551 182 A1	07/14/93	Europe	ļ		<u> </u>	$\vdash$
-	T	B30	EP 0 566 245 A1	10/20/93	Europe			<u> </u>	╁
_	+-	B31	EP 0 577 215	01/05/93	Europe				$\vdash$
	╁┈	B32	EP 0 578 998	01/1994	Europe		<u> </u>		╁
-	╁╌	B33	EP 0 588 518 A1	03/23/94	Europe	<u> </u>	<del>                                     </del>		+
	+	B34	EP 0 606 613	07/20/94	Europe				$\vdash$
	╁╌	B35	EP 0 619 314	10/12/94	Europe				+
	-	B36	EP 0 622 076	11/02/94	Europe			<u> </u>	+
	1	B37	EP 0 639 577	02/22/95	Europe				$\vdash$
	ļ	B38	EP 0 673 936	09/27/95	Europe				+
		B39	EP 0 691 130	01/10/96	Europe				+
	*	B40	EP 0 701 802 A1	03/20/93	Europe	<del> </del>		<del> </del>	+
	<del> </del>	B41	EP 0 706 376 B1	06/25/97	Europe	<u></u>		<b> </b> -	+
	1	B41	EP 0 711 158 B1	12/03/03	Europe	ļ		ļ <del></del>	+
	1	B42	EP 0 717 041 B1	06/19/96	Europe	<del> </del>			+-
	╁	B44	EP 0 747 069	12/11/96	Europe	<del> </del>	<del></del>		╁
	╁╾	B45	EP 0 975 340	10/08/98	Europe	<del> </del>		<b> </b>	╁╴
	*	B45	EP 1 360 967 A1	11/12/03	Europe	<u> </u>			╁
	+	B46 B47	EP 0 290 012	11/09/88	Europe			-	╁
	┼─	B47	EP 0 302 034	02/01/89	Europe	<u> </u>			╁
	┢╌	B49	EP 0 635270	01/25/95	Europe			<del> </del>	╁╴
	╁		EP 0 377 526B1	07/11/90	Europe				┼─
	├	B50	EP 0 524 093	01/20/93	Europe				╁
_	├	B51	EP 0 542 679	05/19/93	Europe				┾
	-	B52	EP 0 551 182	07/14/93	Europe	<del> </del>		ļ	+
+-	-	B53	EP 0 623 354	11/09/94	Europe	<del> </del>		<b></b>	+
-	-	B54	EP 0 623 334 EP 0 629 697	12/21/94	Europe	<del> </del>			+
-	$\vdash$	B55	EP 0 639 577	02/22/95	Europe		ļ	ļ	╁
	$\vdash$	B56	EP 0 659 413 A2	06/28/95	<u> </u>		<del> </del>	<u> </u>	╀
$\mathcal{A}\mathcal{V}$	<b>├</b>	B57 B58	EP 0 639 413 A2	06/28/95	Europe	ļ			4

					01 /	Аррисанов і	140. 10/003	,,113
TB	B59	EP 0 659 418	06/28/95	Еигоре				
	B60	EP 0 659 419 A1	06/28/95	Europe				
	B61	EP 0 659 429 A1	06/28/95	Europe				<u> </u>
	B62	EP 0 664 121	07/26/95	Europe				
	B63	EP 0 664 122	07/26/95	Europe				
	B64	EP 0 664 123	07/26/95	Europe	<del></del>			<del>                                     </del>
	B65	EP 0 664 124 A1	07/26/95	Europe				<b>†</b>
	B66	EP 0 664 125	07/26/95	Europe				<b>†</b>
	B67	EP 0 664 198	07/26/95	Europe				<b>†</b>
	B68	EP 0 665 015	08/02/95	Europe				$\vdash$
	B69	EP 0 668 075	08/23/95	Europe		_		<del>                                     </del>
	B70	EP 0 670 162	09/06/95	Europe				<del>                                     </del>
	B71	EP 0 673 936	09/27/95	Europe				†
	B72	EP 0 674 903	10/04/95	Europe				†
	B73	EP 0 675 121	10/04/95	Europe				<del>                                     </del>
	B74	EP 0 684 259 A1	11/29/95	Europe				<del>                                     </del>
	B75	EP 0 699 673	03/06/96	Europe				
	B76	EP 0 734 721 A2	10/02/96	Europe				
	B77	WO 00/00238	01/06/00	PCT				<del>                                     </del>
	B78	WO 0047197	08/17/00	PCR				<del>                                     </del>
	B79	WO 85/00107	01/17/85	PCT (with English abstract)				
	B80	WO 88/10259	12/29/88	PCT				
	B81	WO 90/01969	03/08/90	PCT				_
<u></u>	B82	WO 90/07328	07/12/90	PCT				
	B83	WO 90/11676	10/18/90	PCT				<u> </u>
	B84	WO 90/12597	11/01/90	PCT				<u> </u>
	B85	WO 90/13293	11/15/90/	PCT				†
	B86	WO 91/08291	06/13/91	PCT				
	B87	WO 91/15219	10/17/91	PCT				1
	B88	WO 91/15222	10/17/91	PCT				
	B89	WO 91/17731	11/28/91	PCT			-	
	B90	WO 91/17789 A1	11/28/91	PCT				
	B91	WO 91/18940 A1	12/12/91	PCT				
	B92	WO 92/00330	01/09/92	PCT			•	
	B93	WO 92/06068	04/16/92	PCT				
	B94	WO 92/08480	05/29/92	PCT				
	B95	WO 92/11872	07/23/92	PCT				
	B96	WO 92/11890	07/23/92	PCT				
	B97	WO 92/11895	07/23/92	PCT				
	B98	WO 92/12717	08/06/92	PCT				$\vdash$
	B99	WO 92/13867	08/20/92	PCT				
	B100	WO 92/18546	10/29/92	PCT				
	B10	WO 92/19273	11/12/92	PCT				
	B102	WO 92/19612	11/12/92	PCT				
,   .	B103	WO 92/21363	12/10/92	PCT	<del>-  -</del>			
$-\Lambda$	B104	WO 93/02065	02/04/93	PCT				

							or Application		7,113
T	'B	B105	WO 93/04191	03/04/93	PCT	<del>-</del> -			
Ī		B106	WO 93/06792 A1	04/15/93	PCT				
		B107	WO 93/07748	04/29/93	PCT				
		B108	WO 93/09228	05/13/93	PCT				
		B109	WO 93/09765	05/27/93	PCT				
		B110	WO 93/09790	05/27/93	PCT				
		B111	WO 93/09800	05/27/93	PCT				
		B112	WO 93/09802	05/27/93	PCT	<del></del>			<u> </u>
		B113	WO 93/10808	06/10/93	PCT	<del></del>			
		B114	WO 93/11120	06/10/93	PCT			<u> </u>	
		B115	WO 93/11757	06/24/93	PCT			<u> </u>	
		B116	WO 93/16724	09/02/93	PCT				
		B117	WO 93/17121	09/02/93	PCT				
		B118	WO 93/19746	10/14/93	PCT				
		B119	WO 93/19769	10/14/93	PCT				
	$-\dagger$	B120	WO 93/24476	12/09/93	PCT				
		B121	WO 94/02595	02/03/94	PCT				
		B122	WO 94/03644	02/17/94	PCT	•			
		B123	WO 94/04164	03/03/94	PCT				
1		B124	WO 94/04178	03/03/94	PCT				
		B125	WO 94/07529	04/14/94	PCT				
		B126	WO 94/08604	04/28/94	PCT				
		B127	WO 94/08605	04/28/94	PCT				
	*	B128	WO 94/09010	04/28/94	PCT				
		B129	WO 94/09764	05/11/94	PCT				
		B130	WO 94/09812	05/11/94	PCT				
		B131	WO 94/10187	05/11/94	PCT	······································			
Í		B132	WO 94/13706	06/23/94	PCT				
		B133	WO 94/15589	07/21/94	PCT				
		B134	WO 94/15590	07/21/94	PCT				
		B135	WO 94/15646	07/21/94	PCT	•			
		B136	WO 94/16706	08/04/94	PCT				
Ī		B137	WO 94/17786	08/18/94	PCT				
		B138	WO 94/18345	08/18/94	PCT				
		B139	WO 94/18954	09/01/94	PCT				
ı		B140	WO 94/18967	09/01/94	PCT				
		B141	WO 94/18968	09/01/94	PCT				
		B142	WO 94/19000	09/01/94	PCT				
		B143	WO 94/19001	09/01/94	PCT				
		B144	WO 94/19003	09/01/94	PCT				
		B145	WO 94/20096	09/25/94	PCT				
		B146	WO 94/20097	09/15/94	PCT				
		B147	WO 94/20098	09/15/94	PCT			_	
		B148	WO 94/20099	09/15/94	PCT				
	,	B149	WO 94/20116	09/15/94	PCT				
$ \blacksquare$		B150	WO 94/20117	09/15/94	PCT				

						cation No. 10/603,11:
TB	B151	WO 94/20126	09/15/94	PCT		
Ī	B152	WO 94/20127	09/15/94	PCT		
	B153	WO 94/21679	09/29/94	PCT		
	B154	WO 94/22436	10/13/94	PCT		
	B155	WO 94/23068	10/13/94	PCT		
	B156	WO 94/23699	10/27/94	PCT		
	B157	WO 94/25020	11/10/94	PCT		
1	B158	WO 94/25053	11/10/94	PCT		
	B159	WO 94/25588	11/10/94	PCT		
	B160	WO 94/26291	11/24/94	PCT		
	B161	WO 94/26303	11/24/94	PCT		
	B162	WO 94/26888	10/06/95	PCT		
	B163	WO 94/27612	12/08/94	PCT		
	B164	WO 94/28721	12/22/94	PCT		
	B165	WO 95/03036	02/02/95	PCT		
1	B166	WO 95/03795	02/02/95	PCT		
	B167	WO 95/04544	02/16/95	PCT		
	B168	WO 95/05191	02/23/95	PCT		
-	B169	WO 95/10611	04/20/95	PCT		
_	B170	WO 95/17095	06/29/95	PCT		
+-	B171	WO 95/19987	07/27/95	PCT		
	B172	WO 95/20582	08/03/95	PCT		
	B173	WO 95/30900	11/16/95	PCT		
-	B174	WO 95/33736	12/14/95	PCT		
-	B175	WO 96/01102	01/18/96	PCT		
	B176	WO 96/03092	02/08/96	PCT		
-	B177	WO 96/07402	03/14/96	PCT		
	B178	WO 96/15224	05/23/96	PCT		<del></del>
<del></del>	B179	WO 96/20698	07/11/96	PCT	-	
	B180	WO 96/21442	07/18/96	PCT		
-	B181	WO 96/21443	07/18/96	PCT	-	<del>-   -   -</del>
+	B182	WO 96/24356	08/15/96	PCT		
<del> </del>	B182	WO 96/25176	08/22/96	PCT		
+	B184	WO 96/36349	11/21/96	PCT		<del></del>
	B185	WO 96/40098	12/19/96	PCT		<del>-  -  -</del>
-	B186	WO 97/10011	03/20/97	PCT		
<del>                                     </del>	B187	WO 97/10334	03/20/97	PCT		
+	B187	WO 97/15319	05/01/97	PCT	<del></del>	
+	B188	WO 97/21455	06/19/97	PCT		<del></del>
+	B189	WO 97/22697	06/26/97	PCT		
+	<del> </del>	WO 97/33552	09/18/97	PCT	<del></del>	<del>-   </del>
₩-	B191	WO 97/45105	12/04/97	PCT		

	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
TB		C01	"Breast Cancer Prevention Trial Should Resume, ODAC Says", The Breast Cancer Letter, 20, 4-5, (June 17, 1994)					
TB	7	C02	"Churchill's Medical Dictionary", definition of "cytostatic", 473, (1989)					

		of Application No. 10/603,115
TB	C03	"Cytochalasins", In: The Merck Index, Eleventh Edition, Merck & Co., Rahway NJ, 438-439 (1989).
	C04	"Glaxo Wellcome Preclinical Data: Preclinical studies conducted with GW 5638, a selective estrogen receptor modulator developed by Glaxo Wellcome, indicate that the compound acts both as an agonist and antagonist at estrogen receptor within specific", R & D Focus Drug News, (September 8, 1997)
	C05	"Growth Factor Via Gene Therapy Abates Sore Rheumatoid Joints", BioWorld Today: The Daily Biotechnology Newspaper, 9(115), Leff, David N., Editor, 1, (June 17, 1998)
	C06	"Health Report The Good News", Time, 23, (Apr. 1, 1996)
	C07	"Heparin", In: Modern Pharmacology, Craig, C.R., et al., (eds.), Little, Brown and Company, Boston, MA, p. 399, (1982)
	C08	"ICI United States, Inc., Tamoxifen citrate, Summary For Basis of Approval", (December 30, 1977)
	C09	"Johnson & Johnson receives FDA approval to market Palmaz Balloon-expandable Stent for iliac arteries," Business Wire, Oct. 2, 1991.
	C10	"Micellar and Lyotropic Liquid Crystalline Phases Containing Nonionic Active Substances", In: Lyotropic Liquid Crystals and the Structure of Biomembranes, S. Fribert, (ed.), Advances in Chemistry Series, No. 152, American Chemical Society, 28-42, (1976)
	C11	"Muscle-Binding Gene Sees Two-Track Payoff: Human Therapies, Animal Meat", BioWorld Today: The Daily Biotechnology Newspaper, 8(85), Leff, David N., Editor, 1-3, (May 2, 1997)
	C12	"Nolvadex Tamoxifene Citrate", ICl Pharma, 64033-02, Rev L/07/92
	C13	"Prevention of Coronary Heart Disease", In: Avery's Drug Treatment — Principles and Practice of Clinical Pharmocology and Therapeutics, Speight, T. M., (ed.), Williams and Wilkins, Baltimore, 594-595, (1987)  "Quantikine — Human TGFbetal Immunoassay", Product Brochure, Catalog No. DB100, R&D Systems, Inc., p. 1-
		19,
	C15	"Schering/Orion Fareston Anti-Estrogen for Treatment of Metastatic Breast Cancer 'Similar' to Tamoxifen, FDA Oncologic Committee Says in Approval Vote", F-D-C Reports, 15-16, (Oct. 23, 1995)
	C16	"Shiga Medical Center for Adult Diseases, "The Impact of Tranilast on Restenosis Following Coronary Angioplasty: The Tranilast Restenosis Following Angioplasty Trial (TREAT)", Circulation, 90, 1-82, Abstract No. 0, (October 1988)
	C17	"Tamoxifen therapy found safe for survivors of breast cancer", Fred Hutchinson Cancer Research Center Newsletter, 1(21), (October 1995)
	C18	"Toprol XLTM Tablets", In: Physician's Desk Reference., 658-660, (Probably 1992)
	C19	Agarwal, A.K., et al., "Estrogen Receptor-Binding Affinity of Tamoxifen Analogs with Various Side Chains and their Biologic Profile in Immature Rat Uterus", Steroids, 56, 486-489, (1991)
	C20	AinMelk, Y., et al., "Tamoxifen Citrate Therapy in Male Fertility", Fertility and Sterility, 48, 113-117, (July 1987)
	C21	Akselband, Y., et al., "Rapamycin Inhibits Spontaneous and Fibroblast Growth Factor Beta-Stimulated Proliferation of Endothelial Cells and Fibroblasts", Transplantation Proceedings, 23, 2833-2836, (1991)
	C22	Alberts, B. et al., "Molecular Biology of the Cell" 2 <sup>nd</sup> edition 1989, p653
	C23	Alberts, B., et al., "Actin Filaments are Continually Formed and Broken Down in Cells", In: Molecular Biology of the Cell, Garland Publishing, London, 571, (1983)
	C24	Alderson, T. 1990 "New targets for cancer chemotherapy – poly(ADP-ribosylation) processing and polyisoprenc metabolism," Biol. Rev. 65:623-641
	C25	Aldridge, D.C., et al., "The Structures of Cytochalasins A and B", J. Chem. Soc., 17, 1667-1676, (1967)
	C26	Alich, A.A., et al., "Comparison of Aspirin and Copper Aspirinate with Respect to Gastric Mucosal Damage in the Rat", Journal of Pharmaceutical Sciences, 72, 1457-1461, (Dec. 1983)
	C27	Alich, A.A., et al., "Gastric Mucosal Damage Due to Aspirin and Copper Aspirinate Assessed by Gastric Mucosal Potential Difference Changes", Journal of Pharmacological and Toxicological Methods, 27, 245-250, (Jul. 1992)
	C28	Alich, A.A., et al., "Response to: 'The Ulcerogenic Potential of Copper Aspirinate Seems to be More Imaginary than Real'", Journal of Pharmaceutical Sciences, 73, Open Forum, 1876-1877, (Dec. 1984)
	C29	Allemann, et al., "Distribution, Kinetics, and Elimination of Radioactivity after Intravenous and Intramuscular Injection of 14C-Savoxepoine Loaded Poly (D,L-lactic acid) Nanospheres to Rats", J. Controlled Release, 29, 97-104, (1994)
	C30	Allemann, et al., "Drug Loaded Poly(Lactic Acid) Nanoparticles Produced by a Reversible Salting-out Process: Purification of an Injectable Dosage Form," Eur. J. Pharm. Biopharm., Vol. 39 (1), pp. 13-18 (1993)
	C31	Allen, K.E., et al., "Evidence For The Metabolic Activation of Non-Steroidal Antioestrogens: A Study of Structure-Activity Relationships", Br.J. Pharmac., 71, 83-91, (1980)
	C32	Allen, R.E. & Boxhor, L.K. "Inhibition of skeletal muscle satellite cell differentiation by transforming growth
	* C33	factor-beta," J Cell. Physiol. 133:567-572.(1987)  Allgemeine und spezielle Pharmakologie und Toxikolgie, by W. Forth et al. 1984, pages 524-531 and 627-633
	C34	Anderson et al., "Restenosis after coronary angioplasty," J. Interv. Cardiol., 6(3)187-202 (1993)
	C35	Anderson, et al., "Effects of Acetate Dialysate on Transforming Growth Factor β <sub>1</sub> Interleukin, and β <sub>2</sub> -Microglobulin Plasma Levels," Kidney International, Vol. 40, pp. 1110-1117 (1991)
V	C36	Ando et al., "Chimeric DNA-RNA hammerhead ribozyme targeting transforming growth factor-beta 1 mRNA inhibits neointima formation in rat carotid artery after balloon injury", Eur. J. Phamacol., 438:207-14 (2004)
		NYJD: 1600258.10

		of Application No. 10/603,115
TB	C37	Anker, et al., "Plasma Levels of the Atherogenic Amino Acid Homocysteine in Post-Menopausal Women with Breast Cancer Treated with Tamoxifen", Int. J. Cancer, 60, 365-368, (1995)
	C38	Arao, Y., et al., "A synthetic oestrogen antagonist, tamoxifen, inhibits oestrogen-induced transcriptional, but not
<b> </b>	<del>-</del>	post-transcriptional, regulation of gene expression", Biochem, J., 313, 269-274, (1996)
	C39	Aschermann, M., "Restenosis After Percutaneous Transluminal Coronary Angioplasty Pathophysiology, New
<del> </del>	-	Trends in Prevention and Treatment," Cor. Vasa., 36:211-218 (1994)
	C40	Askelband et al., "Rapamycin Inhibits Spontaneous and Fibroblast Growth Factor Beta-Stimulated Prolifereation of Endothelial Cells and Fibroblasts," Transplantantion Proceedings, 23 2833-2836 (1991)
	C41	Assoian and Sporn, "Type beta Transforming Growth Factor in Human Platelets: Release During Platelet
		Degranulation and Action on Vascular Smooth Muscle Cells," The Journal of Cell Biology, Vol. 102, pp. 1217-1223 (1986)
	C42	Assoian et al., "Transforming growth factor-beta in human platelets: identification of a major storage site, purification, and characterization", J. Biol. Chem. 258:7155-7160 (1983)
	C43	Assoian, R.K., et al., "Cellular Transformation by Coordinated Action of Three Peptide Growth Factors from Human Platelets", Nature, 309, 804-806, (June 28, 1984)
	C44	Assoian, RK & Spore, M.B. "Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells," J. Cell Biol. 102:1217-1233.(1986)
	C45	Attwood, et al., "A Light Scattering Study on Oil-in-Water Microemulsions" Int'l J. Pharm, 52 165-171 (1989)
	C46	Babaev, et al., "Heterogeneity of smooth muscle cells in atheromatous plaques of human aorta," Am J. Pathol.
	C47	136:1031- 1042. (1990)  Bagdade, et al., "Effects of Tamoxifen Treatment on Plasma Lipids and Lipoprotein Lipid Composition," J. of
<del></del>	<del> </del>	Clinical Endocrinology and Metabolism, Vol. 70, No. 4, pp. 1132-35 (1990)
	C48	Baim, D.S., et al., "Nonatherosclerotic Coronary Heart Disease", In: The Heart: Arteries and Veins, Sixth Edition, Logue, R.B., et al., (eds.), McGraw-Hill Book Company, New York, 1016-1025, (1986)
	C49	Bamburg, James R., "Biological and Biochemical Actions of Trichothecene Mycotoxins," Progress in Molecular and Subcellular Biology", (Hahn F.E., et al., ed.), Springer-Verlag, pp. 41-110) (1983)
	C50	Bang, H.O., et al., "The Composition of the Eskimo Food in North Western Greenland", Am. J. Clin. Nutr., 33, 2657-2661, (1980)
	C51	Baquial, J.G., et al., "Down-Regulation of NADPH-Diaphorase (Nitric Oxide Synthase) May Account for the
		Pharmacological Activities of Cu(II)sub2(3,5-Diisopropylsalicylate)sub4., J. Inorganic Biochem., 60, 133-148, (1995)
	C52	Baral, E., et al., "Modulation of Lymphokine-Activated Killer Cell-Mediated Cytotoxicity By Estradiol and Tamoxifen", Int. J. Cancer, 66, 214-218, (1996)
	C53	Barath, et al., "Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury," JACC, Vol. 13, No. 2, p. 252A Abstract (1989)
	C54	Barbacid, et al., "Binding of [acetyl-14 C] Trichodermin to the Peptidyl Transferase Center of Eukaryotic Ribosomes," Eur. J. Biochem. 44, pp. 437-444 (1974)
	C55	Baringa, "Gene Therapy for Clogged Arteries Passes Test in Pigs", Science, 265, 738 (Aug. 5, 1994)
	C56	Barnard, et al., "Regulation of intestinal epithelial cell growth by transforming growth factor-beta." Proc. Natl Acad. Sci. USA 86:1518-1582.(1989)
	C57	Bartoli et al. "In vitro and in vivo Antitumoral Activity of Free, and Encapsulated taxol". J. Microencapsulation, 7 (2):191-197, 1990
	C58	Basel, C. T., "The Antibiotic Complex of the Verrucarins and Roridins," Fortschr. Chem. Org. Naturst., 31:65 117 (1974)
	C59	Bassing et al., "FKBP12 is not required for the modulation of transforming growth factor beta receptor I signaling activity in embryonic fibroblasts and thymocytes", Cell Growth Differ., 9(3):223-8 (1998)
	C60	Battegay et al., "TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an
	200	autocrine PDGF loop", Cell, 63:5t5-524 (1990)
	C61	Beck, et al., "Poly(DL-Lactide-co-glycolide) /Norethisterone Microcapsules: An Injectable Biodegradable Contraceptive," Biology of Reproduction, Vol. 28, pp. 186-195 (1983)
	C62	Beck, L., et al., "Vascular Development: Cellular and Molecular Regulation", The FASEB Journal, 11, 365-373, (1997)
	C63	Benita et al., "Submicron Emulsions as Colloidal Drug Carries for Intravenous Administration: Comprehensive Physicochemical Characterization", Journal of Pharmaceutical Sciences, 82, (November 1993)
	C64	Bernhardt et al., "Acetylsalicylic acid, at high concentrations, inhibits vascular smooth muscle cell proliferation", J. Cardiovasc. Pharmacol., 21(6):973-6 (1993)
	C65	Bertelli, et al., "Adjuvant Tamoxifen in Primary Breast Cancer: Influence on Plasma Lipids and Antithrombin III Levels," Breast Cancer Res. and Treatment, Vol. 12, pp. 307-310 (1988)
	C66	Berven, L.A., et al., "Cellular Function of p70S6K: A Role in Regulating Cell Motility", Immunology and Cell
	C67	Biology, 78, 447-451, (2000)  Bier et al., "Arterial Remodeling: Importance in Primary Versus Restenoic Lesions", JACC, p. 139A, Abstract No.
	C68	875-96 (February 1994) Billmeyer, F., Textbook of Polymer Science (2d ed.) John Wiley & Sons, Inc. (1971)
<del> \ </del>	C69	Bittiner, S.B., et al., "A Double-Blind, Randomised, Placebo-Controlled Trial of Fish Oil in Psoriasis", The
W L	Coy	Lancet, 1, 378-380, (Feb. 20, 1988)

		of Application No. 10/603,115
TB	C70	Bjorkerud, "Effects of transforming growth factor-betal on human arterial smooth muscle cells in vitro", Arterioscler. Thromb., 11(4):892-902 (1991)
	C71	Block, P.C. "Coronary-artery stents and other endoluminal devices," New Engl.J.Med. 1991; 324-52-3
	C72	Bluming, "Hormone Replacement Therapy: Benefits and Risks for the General Postmenopausal Female Population and for Women with a History of Previously Treated Breast Cancer", Seminars in Oncology, 20, 662-
	C73	674, (December 1993)  Bogyo, et al., "Cytochalasin-β-Induced Immunosuppression of Murine Allogeneic Anti-tumor Response and the
		Effect of Recombinant Human Interleukin-2," Cancer Immunol. Immunother, Vol. 32, pp. 400-405 (1991)
	C74	Bohmova et al., "Effect of sirolimus on ischemia/reperfusion injury in transgenic hypertensive rat", Transplant Proc., 34(8):3051-3052 (2002)
	C75	Border, W.A., et al., "Targeting TGF-Beta for Treatment of Disease", Nature Medicine, 1(10), 1000-1001, (October 1995)
	C76	Boscoboinik et al., "Alpha-tocopherol (vitamin E) regulates vascular smooth muscle cell proliferation and protein kinase C activity", Arch. Biochem. Biophys., 286(1):264-9 (1991)
	C77	Bousquet, et al., "Effects of Cytochalasin β in Culture and in Vivo on Murine Madison 109 Lung Carcinoma and on B16 Melanoma," Cancer Res., Vol. 50, pp. 1431-39 (1990)
	C78	Boyle, "Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture", Curr. Vasc. Pharmacol., 3(1):63-8 (2005)
	C79	Brand, C., et al., "Transforming Growth Factor Betal Decreases Cholesterol Supply to Mitochondria via Repression of Steroidogenic Acute Regulatory Protein Expression", The Journal of Biochemistry, 273(11), 6410-6416, (1998)
	C80	Braun-Dullaeus et al., "Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin", Arterioscler Thromb Vasc Biol. 21(7):1152-58 (2001)
	C81	Brem et al., "Polymers as Controlled Drug Delivery Devices for the Treatment of Malignant Brain Tumours."  European Journal of Pharmaceuticals and Biopharmaceutics, 1993, Vol. 39, No. 1, pp 2-7
	C82	Brody, J.E., "Study Finds New Estrogen Offers Benefit Without Risk", The New York Times, A32, (December 4, 1997)
	C83	Brott et al., "Vessel Remodeling After Angioplasty: Comparative Anatomic Studies", JACC, p. 138A, Abstract No. 875-43 (February 1994)
	C84	Bruengger, et al., "Smooth Muscle Cell of the Canine Prostate in Spontaneous Benign Hyperplasia, Steroid Induced Hyperplasia and Estrogen or Tamoxifen Treated Dogs," J. Urol. Vol. 130, No. 6, pp. 1208-10 (1983)
	C85	Bruning, et al., "Tamoxifen, Serum Lipoproteins and Cardiovascular Risk", Br. J. Cancer, 58, 497-499 (1988)
	C86	Bumol, et al., "Unique Glycoprotein-Proteoglycan Complex Defined by Monoclonal Antibody on Human Melanoma Cells," PNAS (USA), Vol. 79, pp. 1245-49 (1982)
	C87	Burr, M.L., et al., "Effects of Changes in Fat, Fish and ibre Intakes on Death and Myocardial Reinfarction: Diat and Reinfarction Trial (DART)", The Lancet, 757-761, (Sep. 30, 1989)
	C88	Burton, T.M., "Lilly Osteoporosis Treatment Shows Promise", The Wall Street Journal, p. A3, A6, (June 6, 1997)
	C89	Butta, et al., "Induction of Transforming Growth Factor β <sub>1</sub> in Human Breast Cancer in vivo Following Tamoxifen Treatment," Cancer Res. Vol. 52, pp. 4261-64 (1992)
	C90	C. Chamsangavej et al., A New Expandable Metallic Stent for Dilation of Stenotic Tubular Structures:  Experimental and Clinical Evaluation, Houston Medical Journal 1987;2:41-51
	C91	C. T. Dotter, "Transluminally Placed Coil Spring Endarterial Tube Grafts Long Term Patency in Canine Popliteal Arteries," Investigative Radiology 1969;4:329-332.
	C92	Calver et al. "Intracoronary Multi-link stents: experience in 218 patients using aspirin alone," Heart 1998;80:499-504
	C93	Camenzind, et al., "Use of Locally Delivered Conventional Drug Therapies", Semin. Intervent. Cardiol., 1, 67-76 (1996)
	C94	Cannon, M., et al., "Competition Between Trichodermin and Several Other Sesquiterpene Antibiotics for Binding to their Receptor Site(s) on Eukaryotic Ribosomes", Biochem. J., 160, 137-145, (1976)
	C95	Casscells, W., et al., "Elimination of Smooth Muscle Cells in Experimental Restenosis: Targeting of Fibroblast Growth Factor Receptors", Proc. Natl. Acad. Sci. USA, 89, 7159-7163 (1992)
	C96	Castellot et al., "Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth", J. Cell Biol., 90:372-379 (1981)
	C97	Castellot et al., "Effect of heparin on vascular smooth muscle cells. I. Cell metabolism", J. Cell. Physiol., 124:21-28 (1985)
	C98	Castellot et al., Heparin selectively inhibits a protein kinase c-dependent mechanism of cell cycle progression in calf aortic smooth muscle cells, J Cell Biol., 109:3147-3155 (1989)
	C99	Chaldakov, et al., "Cyclic AMP-and Cytochalasin B-induced Arborization in Cultured Aortic Smooth Muscle Cells: Its Cytopharmacological Characterization," Cell Tissue Res. Vol. 255, pp. 435-442 (1989)
	C100	Chamberlain, 'Transforming growth factor-beta: a promising target for anti-stenosis therapy", Cardiovasc. Drug Rev., 19(4):329-344 (2001)
	C101	Chamley-Campbell and Campbell, "What controls smooth muscle phenotype?", Atherosclerosis, 40:347-357 (1981)
	C102	Chamsangavej et al., "Endovascular Stent for Vena Caval Stenosis: Laboratory Experiment and Potential Clinical

		of Application No. 10/603,115
TB		Applications," Radiology 1985 Nov;157(P):66 Abs. 129.
1	C103	Chander, et al., "Pyrrolidino-4-iodotamoxifen and 4-lodotamoxifen, New Analogues of the Antiestrogen Tamoxifen for the Treatment of Breast Cancer," Cancer Research, Vol. 51, pp. 5851-5858 (1991)
	C104	Chandrasekar, B., et al., "Dietary Omega-3 Lipids Delay the Onset and Progression of Autoimmune Lupus Nephritis by Inhibiting Transforming Growth Factor Beta mRNA and Protein Expression", Journal of Autoimmunity, 8, 381-393, (1995)
	C105	Chandy, T., et al., "Chitosan Matrix for Oral Sustained Delivery of Ampicillin", Biomaterials, 14, 939-944, (1993)
	C106	Chang, M.P., et al., "Comparison of the Intoxication Pathways of Tumor Necrosis Factor and Diphtheria Toxin", Infection and Immunity, 58, 2644-2650, (Aug., 1990)
	C107	Chao, et al., "Altered Cytokine Release in Peripheral Blood Mononuclear Cell Cultures from Patients with the Chronic Fatigue Syndrome," Cytokine, Vol. 3, No. 4, pp. 292-298 (1991)
	C108	Chapman, et al., "A Bioabsorbable Stent: Initial Experimental Results," Supplement III Cir., Vol. 82, No. 4, p. III-72 (1990)
	C109	Charles Dotter et al., "Transluminal Treatment of Arteriosclerotic Obstruction Description of a New Technique and a Preliminary Report of its Application," Circulation 1964;30:654-669
	C110	Charlier, C., et al., "Tamoxifen and Its Active Metabolite Inhibit Growth of Estrogen Receptor-Negative MDA-MB-435 cells", Biochemical Pharmacology, 49(3), 351-358, (January 1995)
	CIII	Charlier, et al., "Tamoxifen in the Treatment of Breast Cancer", J. Gynecol. Obstet Biol. Reprod., 23, 751-756, (1994)
	C112	Charmsangavej, et al., "Stenosis of the Vena Cava: Preliminary Assessment of Treatment with Expandable Metallic Stents," Radiology 1986 Nov;161:295.
	C113	Chauhan et al., "Activation of Transforming Growth Factor-B is Inversely Correlated with Three Major Risk Factors for Coronary Artery Disease: Lipoprotein(a), LDL-Cholesterol and Plasminogen Activator Inhibitor-1", Circulation, 90 I-623, Abstract No. 3354 (October 1994)
	C114	Cheitlin, M.D., et al., "Myocardial Infarction without Atherosclerosis", JAMA, 231, 951-959, (1975)
	C115	Chen et al., "Transforming growth factor type beta specifically stimulates synthesis of proteoglycan in human adult arterial smooth muscle cells", Proc. Natl. Acad. Sci., 84:5287-5291 (1987)
	C116	Clark, D.A., et al., "Coronary Artery Spasm: Medical Management, Surgical Denegration, and Autotransplantation", The Journal of Thoracic and Cardiovascular Surgery, 73, 332-339, (1977)
	C117	Clarke, S.C., et al., "Tolerance and Responses To Tamoxifen and Toremifene in Male Patients with Coronary Artery Disease.", Abstract for ACC Meeting, March 1999
	C118	Clinton, S.K., "Induction in vivo of Interleukin-1 (IL-1) Gene Expression in Rabbit Aortic Tissue", Abstracts of the 61st Scientific Sessions, II-65
	C119	Clowes and Kamowsky, "Suppression by heparin of smooth muscle cell proliferation in injured arteries", Nature, 265:625-626 (1977)
	C120	Clowes et al., "Heparin and cilazapril together inhibit injury-induced intimal hyperplasia", Hypertension, 18:II-65-II-69 (1991)
	C121	Clowes et al., "Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery," Cir. Res. Vol. 56, No. 1, pp. 139-145 (1985)
	C122	Clowes, et al. "Mechanisms of Stenosis After Arterial Injury", Laboratory Investigation, Vol. 49, No. 2, pp. 208-215 (1983)
	C123	Clowes, et al., "Kinetics of Cellular Proliferation After Arterial Injury - I. Smooth Muscle Growth in the Absence of Endothelium", Laboratory Investigation, Vol. 49, No. 3, pp. 327-333 (1983)
	C124	Clowes, et al., "Kinetics of Cellular Proliferation After Arterial Injury - III, Endothelial and Smooth Muscle Growth in Chronically Denuded Vessels", Laboratory Investigation, Vol. 54, No. 3, pp. 295-303 (1986)
	C125	Cole, R. J. et al., "The Cytochalasins", In: Handbook of Toxic Fungal Metabolics, Academic Press, New York, p. 264-265, 281-282 (1981)
	C126	Colletta, A.A. et al., "Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts", Br. J. Cancer, 62, 405-409, (1990)
	C127	Columbo et al., "A Novel Strategy for Stent Deployment in the Treatment of Acute or Threatened Closure Complicating Balloon Coronary Angioplasty," JACC 1993 Dec;22(7):1887-91,
	C128	Comezoglu, F.T. et al., "Serum Stability and Cytotoxicity of the Macrocyclic Trichothecenes Roridin A, Verrucarin A and Their Monoclonal Antibody Conjugates", Proceedings of the American Association for Cancer Research, 31, Abstract No. 1723, p. 291, (Mar., 1990)
	C129	Coomber and Gotlieb "In vitro endothelial wound repair. Interaction of cell migration and proliferation".  Ateriosclerosis, 10 (2):215-222, 1990
	C130	Coombes, R.C., et al., "Idoxifene: Report of a Phase I Study in Patients with Metastatic Breast Cancer", Cancer Research, 55, 1070-1074, (Mar. 1, 1995)
	C131	Corcos, et al., "Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty", Am. Heart J., 109(5):926-931 (1985)
	C132	Cotton, P., "Restenosis Trials Suggest Role for Remodeling", JAMA, 271, 1302-1305, (May 4, 1994)
V	C133	Cowsar, et al., "Poly(Lactide-co-glycolide) Microcapsules for Controlled Release of Steroids," Methods in Enzymology, Vol. 112, pp. 101-117 (1985)

		01 Application No. 10/603,113
TB	C134	Cox et al., "Effects of local delivery of heparin and methotrexate on neointimal proliferation in stented porcine coronary arteries". Coronary Artery Disease, 3:237-248, 1992
	C135	Cox et al., "Local Delivery of Heperin and methotrexate fails to inhibit in vivo smooth muscle cell proliferation". Circulation Suppl. 84(4):II-71, #0284, 1991
	C136	Craig et al., "Anticoagulant Drugs" in Modern Pharmacology; Little, Brown & Co.: Boston; p. 399 (1982)
	C137	Crissman, et al., "Transformed Mammalian Cells are Deficient in Kinase-Mediated Control of Progression Through the G <sub>1</sub> Phase of the Cell Cycle," PNAS (USA), Vol. 88, pp. 7580-84 (1991)
	C138	Csernok, E., et al., "Transforming Growth Factor-beta (TGF-beta) Expression and Interaction with Proteinase 3
	,	(PR3) in Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis", Clin. Exp. Immunol., 105, 104-111, (1996)
	C139	Cunningham, A., et al., "A Study of the Structural Basis of the Carcinogenicity of Tamoxifen, Toremifene and their Metabolites", Mutation Research, 349, 85-94, (1996)
	C140	Currier, "Restenosis After Percutaneous Transluminal Coronary Angioplasty: Have We Been Aiming at the Wrong Target?", JACC, 25 516-520 (February 1995)
	C141	Dangas, G., et al., "Management of Restenosis after Coronary Intervention", American Heart Journal, 132, 428-436, (1996)
	C142	Danielpour, David, "Improved Sandwich Enzyme-Linked Immunosorbent Assays for Transforming Growth Factor," Journal of Immunological Methods, Vol. 158, pp. 17-25 (1993)
	C143	Danielpour, et al., "Evidence for Differential Regulator of TGF\(\beta\)1 and TGF\(\beta\)2 Expression in Vivo by Sandwich Enzyme-linked Immunosorbent Assays," Annals New York Academy of Sciences, pp. 300-302
	C144	Danielpour, et al., "Immunodetection and Quantitation of the Two Forms of Transforming Growth Factor-Beta
	C145	(TGF-1 and TGF-2) Secreted by Cells in Culture," Journal of Cellular Physiology, Vol. 138, pp. 79-86 (1989)  Dasch, et al., "Capture Immunoassays Specific for TGF1 and TGF2: Use in Pharmacokinetic Studies," Annals
		New York Academy of Sciences, pp. 303-305
	C146	Davies, A.M., et al., "Peroxidase Activation of Tamoxifen and Toremifene Resulting in DNA Damage and Covalently Bound Protein Adducts", Carcinogenesis, 16, 539-545, (1995)
	C147	deAlvare, L.R., et al., "Mechanism of Superoxlde Anion Scavenging Reaction by Bis-(Salicylato)-Copper(II) Complex", Biochemical and Biophysical Research Communications, 69, 687-694, (1976)
	C148	Dehmer, G.J., et al., "Reduction in the Rate of Early Restenosis After Coronary Angioplasty by a Diet Supplemented with n-3 Fatty Acids", N. Engl. J. Med., 319, 733-740, (1988)
	C149	Del Vecchio et al., "Inhibition of human scleral fibroblast proliferation with heparin, Invest" Ophthalmol. Vis. Sci., 29:1272-1276 (1988)
	C150	Delmas, P.D., "Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine
	C151	Endometrium in Postmenopausal Women", The New England Journal of Medicine, 337(23), (1997)  Detre, et al., "Percutaneous Transluminal Coronary Angioplasty in 1985-1986 and 1977-1981", The New England
	C152	J. of Med., Vol 318, No. 5, pp. 265-270 (1988)  DiGiacomo, R.A., et al., "Fish-Oil Dietary Supplementation in Patients with Raynaud's Phenomenon: A Double-
<del>       </del>	C153	Blind, Controlled, Prospective Study", Am. J. Med., 86, 158-164, (Feb. 1989)  DiLuccio, R.C., et al., "Sustained-Release Oral Delivery of Theophylline by Use of Polyvinyl Alcohol and
	(133	Polyvinyl Alcohol-Methyl Acrylate Polymers", Journal of Pharmaceutical Sciences, 83, 104-106, (January 1994)
	C154	DiMario, "Is the Mechanism of Restenosis Device-Independent? Serial Assessment with Intracoronary Ultrasound", Circulation, 90, I-24, Abstract 115 (October 1994)
	C155	Dimond, Patricia F., Ph.D., "TGF-Beta Shows Potential as Therapeutic Agent for Macular Holes," Genetic Engineering News, pp. 7 & 19 (1993)
	C156	Donnelly, J., et al., "Protective Efficacy of Intramuscular Immunization with Naked DNA; DNA Vaccines: A New Era in Vaccinology, Margaret A. Liu et al., eds.", Annals of the New York Academy of Sciences, 772, 40-44,
	C157	(1995)   Dotter, "Intraventional Radiology – Review of an Emerging Field," Seminars In Roentgenology 1982;16(1):7-8,
	C157	Dove, C.R., et al., "Effect of Vitamin E and Copper on the Vitamin E Status and Performance of Growing Pigs", J.
	C159	Anim. Sci., 69, 2516-2523, (1991)  Dowsett, M., "New Developments in the Hormonal Treatment of Breast Cancer", In: The Treatment of Cancer:
<del>   </del>	C160	Beyond Chemotherapy, Conference Documentation, The Glouster Hotel, London, 7 p., (Mar. 13-14, 1995)  Dragan, Y.P., et al., "Comparison of the Effects of Tamoxifen and Toremifene on Liver and Kidney Tumor
	C161	Promotion in Female Rats", Carcinogenesis, 16, 2733-2741, (1995)  Draper, M.W., et al., "Antiestrogenic Properties of Raloxifene", Pharmacology, 50, 209-217, (April 1995)
	C161	Dyerberg, J., "PlateletVessel Wall Interaction: Influence of Diet", Phil. Trans. R. Soc. Lond., B 294, 372-381,
	C163	(1981)  Dyerberg, J., et al., "The Effect of Arachidonic- and Eicosapentaenoic Acid on the Synthesis of Prostacyclin-like
	C164	Material in Human Umbilical Vasculature", Artery, 8, 12-17, (1980)  Ebner, et al., "Cloning of a Type I TGF-β Receptor and Its Effect on TGF-β Binding to the Type II Receptor,"
	_	Science, Vol. 260, pp. 1344-48 (1993)  Edelman, E.R., et al., "Effect of Controlled Adventitial Heparin Delivery on Smooth Muscle Cell Proliferation
	C165	Following Endothelial Injury", Proc. Natl. Acad. Sci. USA, 87, 3773-3777, (May, 1990)
$\lfloor V \rfloor$	C166	Eldridge, et al., "Biodegradable and Biocompatible Poly(DL-Lactide-CO-Glycolide) Microspheres as an Adjuvant for Staphylococcal Enterotoxin B Toxoid which Enhances the Level of Toxin-Neutralizing Antibodies," Infection
<b>└</b>		itor Staphyrococcal Enterotoxin of Toxord which Enhances the Level of Toxin-Neutralizing Antibodies," Infection

			of Application No. 10/603,115
I	rB		and Immunity, 59(9):2978-2986 (1991)
I		C167	Ellis et al., "Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty", Am, Heart J., 117(4):777-782 (1989)
		C168	Ellis, S.G., et al., "In-Hospital Cost of Percutaneous Coronary Revascularization: Critical Determinants and Implications", Circulation, 92, 741-747, (1995)
		C169	Endres, S., et al., "The Effect of Dietary Supplementation with n-3 polyunsaturated Fatty Acids on the Synthesis of Interleukin-1 and Tumor Necrosis Factor by Mononuclear Cells", N. Engl. J. Med., 320, 265-271, 1989)
		C170	Epstein, Stephen E., MD., "Cytotoxic Effects of a Recombinant Chimeric Toxin on Rapidly Proliferating Vascular Smooth Muscle Cells," Cir. Vol. 84, No. 2, pp. 778-787 (1991)
		C171	Esnouf, M.P., et al., "The Inhibition of the Vitamin K-Dependent Carboxylation of Glutamyl Residues in Prothombin by Some Copper Complexes", FEBS Letters, 107, 146-150, (1979)
		C172	Espinosa, E., et al., "17-Estradiol and Smooth Muscle Cell Proliferation in Aortic Cells of Male and Female Rats", Biochemical and Biophysical Research Communication, 221, 8-14, (1996)
		C173	Ettenson and Gotlieb "Centrosomes, Microtubules, and Microfilaments in the Reendothelialization and Remodeling of Double-Sided In Vitro Wounds". Laboratory Investigation, Vol. 68, No. 6, pp. 722-733, 1992, United States and Canadian Academy of Pathology, Inc.
		C174	Evans, G.L., et al., "Tissue-Selective Actions of Estrogen Analogs", Bone, 17, 181S-190S, (October 1995)
		C175	Fanelli, et al., "Restenosis Following Coronary Angioplasty", Amer. Heart J., Vol 119, No. 2, Part 1, pp. 357-368 (1990)
·		C176	Farhat, et al., "In Vitro Effect of Oestradiol on Thymidine Uptake in Pulmonary Vascular Smooth Muscle Cell: Role of the Endothelium," Br. J. Pharmacol. Vol. 107, pp. 679-683 (1992)
		C177	Faxon et al., "Enozaprain, a low molecular weight heparin, in the prevention of restenosis after angioplasty: results of a double blind randomized trial", JACC 19:258A, Abstract 783-3 (1992)
		C178	Faxon et al., "Restenosis Following Transluminal Angioplasty in Experimental Atherosclerosis", Arteriosclerosis, Vol. 4, No. 3, pp. 189-195 (1984)
		C179	Fay, et al., "Effects of Cytochalasin B On The Uptake of Ascorbic Acid and Glucose By 3T3 Fibroblasts:  Mechanism of Impaired Ascorbate Transport in Diabetes," Life Sci., Vol. 46, pp. 619-624 (1990) (USA)
		C180	Feelisch, et al., "Biotransformation of Organic Nitrates to Nitric Oxide by Vascular Smooth Muscle and Endothelial Cells," Biochemical and Biophysical Research Communications, Vol. 180, No. 1, pp. 286-293 (1991)
		C181	Ferrari, R.P., et al., "Changes of Serum Iron Transferrin and Copper Ceruloplasmin in Rats Given Cu(II) sub2 (Acetylsalicyate) sub4 During Acute Inflammation", Anticancer Res., 9, 771-774, (1989)
		C182	Fett-Neto, A.G., et al., "Effect of White Light on Taxol and Baccatin III Accumulation in Cell Cultures of Taxus Cuspidata Sieb and Zucc.", J. Plant Physiol., 146, 584-590, (1995)
		C183	Fischell, et al., "Low-Dose, beta-Particle Emission From 'Stent' Wire Results in Complete, Localize Inhibition of Smooth Muscle Cell Proliferation", Circulation, 90 2956-2963 (December, 1994)
		C184	Fischer, et al., "A Possible Mechanism in Arterial Wall for Mediation of Sex Difference in Atherosclerosis Experimental and Molecular Pathology", Exp. Mol. Pathol., 43 288-296 (1985)
		C185	Fischman, et al., "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease:, The New England Journal of Medicine, 331, 496-501 (August, 1994)
		C186	Fisher, M., et al., "Dietary n-3 Fatty Acid Supplementation Reduces Superoxide Production and Chemiluminescence in a Monocyte-Enriched Preparation of Leukocytes", Am. J. Clin. Nutr., 51, 804-808, (1990)
		C187	Flanders, K.C., et al., "Altered Expression of Transforming Growth Factor-B in Alzheimer's Disease", Neurology, 45, 1561-1569, (August 1995)
		C188	
		C189	Foekens, J.A., et al., "Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1: Predictors of Poor Response to Tamoxifen Therapy in Recurrent Breast Cancer", Journal of the National Cancer Institute, 87(10), 751-756, (May 1995)
		C190	Forney-Prescott et al., "Angiotensin-converting enzyme inhibito' versus angiotensin II, AT1 receptor antagonist: effects on smooth muscle cell migration and proliferation after balloon catheter injury", Am J Pathol, 139:1291-1296 (1991)
		C191	Forrester, J.S., et al., "A Paradigm for Restenosis Based on Cell Biology: Clues for the Development of New Preventive Therapies: JACC, 17, 758-769, (1991)
		C192	Fox and DiCorleto, "Fish oils inhibit endothelial cell production of platelet-derived growth factor-like protein", Science, 241 (4864):453-456 (1988)
		C193	Frautschy, S.A., et al., "Rodent Models of Alzheimer's Disease: Rat A Infusion Approaches to Amyloid
		C194	Deposits", Neurobiology of Aging, 17, 311-321, (1996)  Frazier-Jessen, et al., "Estrogen Modulation of JE/Monocytte Chemoattractant Protein-1 mRNA Expression in Murine Macrophages", J. Immunol., 1828-1845
		C195	Friberg, et al., "Microemulsions and Solubilization by Nonionic Surfactants", Prog. Colloid and Polymer Sci., 56, 16-20 (1975)
		C196	Frye, L.L., et al., "Oxolanosterol Oximes: Dual-Action Inhibitors of Cholesterol Biosynthesis", Journal of Lipid Research, 35, 11333-1344, (1994)
$\overline{V}$		C197	Fukaura, H., et al., "Induction of Circulating Myelin Basic Protein and Proteolipid Protein-Specific Transforming Growth Factor- B1-secreting Th3 T Cells by Oral Administration of Myelin in Multiple Sclerosis Patients", J.

			of Application No. 10/603,115
	TB		Clin. Invest., 98, 70-77, (1996)
		C198	Fukuda, et al., "Distinct Expression of Transforming Growth Factor-B Receptor Subtypes on Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats and Wistar-Kyoto Rats", Clin. Exp. Pharmacol. Physiol. Supply., 1, S120, 1995
		C199	Fulop, et al., "Age-Dependent Variations of Intralysosomal Enzyme Release from Human PMN Leukocytes Under Various Stimuli," Immunobiol., Vol. 171, pp. 302-310 (1986)
		C200	Furr, B.J., et al., "The Pharmacology and Clinical Uses of Tamoxifen", Pharmac. Ther., 25, 127-205, (1984)
		C201	Garg, U.C., et al., "Nitric Oxide-Generating Vasodilators and 8-Bromo-Cyclic Guanosine Monophosphate Inhibit Mitogenesis and Proliferation of Cultured Rat Vascular Smooth Muscle Cells", Journal of Clinical Investigation, 83, 1774-1777, (May, 1989)
		C202	Garrigues, et al., "The Melanoma Proteoglycan: Restricted Expression on Microspikes, a Specific Microdomain of the Cell Surface," J. Cell Biol. Vol. 103, pp 1699-1710 (1986)
		C203	Gasco, et al., "In Vitro Permeation of Azelaic Acid from Viscosized Microemulsions", International Journal of Pharmaceutics, 69, 193-196 (1991)
		C204	Gasco, M. R., et al., "Long-acting Delivery Systems for Peptides: Reduced Plasma Testosterone Levels in Male Rats after a Single Injection:, Intl. J. of Pharmaceut, 62 119-123 (1990)
		C205	Gebhardt, R., et al., "Differential Inhibitory Effects of Garlie-Derived Organosulfur Compounds on Cholesterol Biosynthesis in Primary Rat Hepatocyte Cultures", Lipids, 31, 1269-1276, (1996)
		C206	Gebhardt, R., et al., "Inhibition of Cholesterol Biosynthesis by Allicin and Ajoene in Rat Hepatocytes and HepG2 Cells", Biochimica et Biophysica Acta, 1213, 57-62, (1994)
		C207	Gertz et al., "Geometric Remodeling Is Not the Principal Pathogenic Process in Restoenosis After Balloon Angioplasty", Circulation, 90, 3001-3008 (December 1994)
		C208	Giachelli, et al., "Osteopontin is Elevated During Neointima Formation in Rat Arteries and is a Novel Component of Human Atherosclerosis Plaques", J. Clin. Invest., 92, 1686-1696, (Oct. 1993)
	1	C209	Gibbons et al., "The emerging concept of vascular remodeling", New Engl. J. of Medicine, 330 1431-1437 (1994)
		C210	Gibson, D.M., et al., "Initiation and Growth of Cell Lines of Taxus Brevifolia (Pacific Yew)", Plant Cell Reports, 12, 479-482, (1993)
		C211	Glagov, et al., "Compensatory Enlargement of Human Atherosclerotic Coronary Arteries," New England J. of Med., Vol. 316 No. 22, p. 1371-1375 (1987)
		C212	Glagov, S., "Intimal Hyperplasia, Vascular Modeling, and the Restenosis Problem", Circulation, 89, 2888-2891, (1994)
		C213	Goldman, et al., "Influence of Pressure on Permeability of Normal and Diseased Muscular Arteries to Horseradish Peroxidase," Atherosclerosis, Vol. 65, pp, 215-225 (1987)
		C214	Goodnight, S.H., "The Effects of n-3 Fatty Acids on Atherosclerosis and the Vascular Response to Injury", Arch. Pathol. Lab. Med., 117, 102-106, (January, 1993)
		C215	Gradishar, W.J., et al., "Clinical Potential of New Antiestrogens", Journal of Clinical Oncology, 15, 840-852, (1997)
		C216	Graham et al., "Dexamethasone Inhibits Grown and Na:H Exchange in Vascular Smooth Muscle Cells" Journal of Endocrinology, 129 (Suppl.) Abstract 180, 10 <sup>th</sup> Joint Metting of British Endocdrine Societies, Brighton, England, UK, April 15-18, (1991)
		C217	Grainger and Metcalfe, "Transforming growth factor-β and cardiovascular protection, draft" (NeoRx 019151-019213)
		C218	Grainger and Metcalfe, TGF-beta: implications for human vascular disease. J Hum Hypertens., 9(8):679 (1995)
		C219	Grainger and Mosedale, "TGF- β and the cardiovascular system, TGF- β and Related Cytokines in Inflammation," Breit, SN and Wahl, SM (ed.), Birkhauser Verlag, 91-146 (2001) (DJG 006134-006190).
		C220	Grainger et al., "Dietary fat and reduced levels of TGFbeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions", J. Cell Sci., 113:2355-2361(2000)
		C221	Grainger et al., "Red wine, but not white wine, elevates circulating TGF- β levels -possible role of a salicylate complex," DJG 003915-003920.
		C222	Grainger et al., "Transforming growth factor-beta dynamically regulates vascular smooth muscele cell differentiation in vivo", J. Cell Sci., 111:2977-2988 (1998)
		C223	Grainger, D.J., "Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis", Arterioscler. Thromb. Vasc. Biol., 24:399-404 (2004) (DJG 006208-006213)
		C224	Grainger, D.J., et al., "A Pivotal Role for TGF-Beta in Atherogenesis?", Biol. Rev., 70, 571-596, (1995)
		C225	Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited by Apolipoprotein (a) in vivo", Circulation, 90, 67 <sup>th</sup> Scientific Session, Abstract No. 3353, p. I-623, (Oct., 1994)
		C226	Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited in Transgenic Apolipoprotein (a) Mice", Nature, 370 460-462, (Aug. 11, 1994)
		C227	Grainger, D.J., et al., "Active and Acid-Activatable TGF-beta in Human Sera, Platelets and Plasma", Clinica Chemica Acta., 235, 11-31, (Feb., 1995)
		C228	Grainger, D.J., et al., "Active TGF-beta is Depressed Five-fold in Triple Vessel Disease Patients Compared with Syndrome X Patients", Journal of Cellular Biochemistry, 18A, Abstract No. E111, p. 267, (1994)
$\lfloor \rfloor$		C229	Grainger, D.J., et al., "Active Transforming Growth Factor-beta is Depressed in Patients with Three Vessel Coronary Artery Disease", Circulation, 90, 67th Scientific Sessions, Abstract No. 2754, p. 1-512, (Oct., 1994)

		of Application No. 10/603,115
TB	C230	Grainger, D.J., et al., "Hexamethylenebisacetamide Selectively Inhibits the Proliferation of Human and Rat Vascular Smooth-Muscle Cells", Biochemical Journal, 283, 403-408, (1992)
<u> </u>	C231	Grainger, D.J., et al., "Mitogens for Adult Rat Aortic Vascular Smooth Muscle Cells in Serum-Free Primary Culture", Cardiovascular Research, 28, 1238-1242, (1994)
	<del>   </del>	
	C232	Grainger, D.J., et al., "Proliferation of Human Smooth Muscle Cells Promoted by Lipoprotein(a)", Science, 260, 1655-1658, (June 11, 1993)
	C233	Grainger, D.J., et al., "Release and Activation of Platelet Latent TFG-Beta in Blood Clots During Dissolution with Plasmin", Nature Medicine, 1, 932-937, (1995)
	C234	Grainger, D.J., et al., "Tamoxifen Elevates Transforming Growth Factor-beta and Suppresses Diet-Induced Formation of Lipid Lesions in Mouse Aorta", Nature Medicine, 1, 1067-1073, (Oct., 1995)
	<del>  </del>	
	C235	Grainger, D.J., et al., "Tamoxifen: Teaching an Old Drug New Tricks?", Nature Medicine, 2, 381-385, (Apr., 1996)
	C236	Grainger, D.J., et al., "The Serum Concentration of Active Transforming Growth Factor-beta is Severely Depressed in Advanced Atherosclerosis", Nature Medicine, 1, 74-80, (Jan., 1995)
1	C237	Grainger, D.J., et al., "Transforming Growth Factor beta Decreases the Rate of Proliferation of Rat Vascular
		Smooth Muscle Cells by Extending the G2 Phase of the Cell Cycle and Delays the Rise in Cyclic AMP Before Entry into M Phase", Biochemical Journal, 299, 227-235, (1994)
	C228	Grainger, D.J., et al., "Transforming Growth Factor-beta and Cardiovascular Protection", In: The Eendothelium in
	C238	Clinical Practice, Rubanyi, G.M., et al., (eds.), Marcel Dekker, Inc., New York, 203-243, (1997)
	C239	Grainger, D.J., et al., "Transforming Growth Factor-beta is Sequestered into an Inactive Pool by Lipoproteins", Journal of Lipid Research, 38, 117-125, (1997)
	C240	Grainger, D.J., et al., "Transforming Growth Factor-beta: The Key to Understanding Lipoprotein(a)?", Current
ŀ		Opinion In Lipidology, 6, 81-85, (1995)
	C241	Grainger, D.J., University of Cambridge Ph.D. Thesis, Control of the proliferation and differentiation of vascular
		smooth muscle cells, DJG 005911-006102 (1992) and all references therein
	C242	Grainger, et al., "Heparin decreases the rate of proliferation of rat vascular smooth muscle cells by releasing
	1	transforming growth factor-like activity from serum," Cardiovascular Research, Vol 27, pp. 2238-47 (1993)
	C243	Grainger, et al., "Tamoxifen Decreases the Rate of Proliferation of Rat Vascular Smooth Muscle Cells in Culture by Inducing Production of Transforming Growth Factor β," Biochem J. Vol. 294, pp. 109-112 (1993)
	C244	Grainger, et al., A Large Accumulation of Non-Muscle Myosin Occurs at First Entry into M Phase in Rat Vascular
1	0244	Smooth-Muscle Cells," Biochem. J. Vol. 277, pp. 145-151 (1991)
	C245	Gref, et al., "Biodegradable Long-Circulating Polymeric Nanoshoeres", Science, 263, 1600-1603, (March 18, 1994)
	C246	Gregory et al., "Rapamycin Inhibits Arterial Intimal Thickening Caused by Both Alloimmune and Mechanical
	<u> </u>	Injury:, Transplantation, 55 1409-1418 (1993)
	C247	Gregory et al., "Treatment with rapamycin blocks arterial intimal thickening following mechanical and alloimmune injury", Transplant. Proc., 25:120-21 (1993)
	C248	Gregory, et al. "Effects of Treatment with Cyclosporine, FK 506, Rapamycin, Mycophenolic Acid, or
	1	Deoxyspergualin on Vascular Muscle Proliferation in Vivo," Transplantation Proceedings, 25:770-771 (1993)
	C249	Grese, T.A., et al., "Structure-Activity Relationships of Selective Estrogen Receptor Modulators: Modification to the 2-Arylbenzothiophene Core of Raloxifene", J. Med. Chem., 40, 146-167, (1997)
	C250	Grey, A.B., et al., "The Effect of the Anti-Estrogen Tamoxifen on Cardiovascular Risk Factors in Normal
J		Postmenopausal Women", J. Clinical Endocrinology and Metabolism, 80, 3191-3195, (1995)
	C251	Grigg, L.É., et al., "Determinants of Restenosis and Lack of Effect of Dietary Supplementation with Eicosapentaenoic Acid on the Incidence of Coronary Artery Restenosis After Angioplasty", JACC, 13, 655-672, (1989)
	C252	Gruntzig, et al., "Nonoperative Dilatation of Coronary-Artery Stenosis," New England J. Med 1979 Jul 12;301(2):61-68.
	C253	Guba et al., "Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of
	<del></del>	vascular endothelial growth factor", Nat. Med., 8(2):128-35 (2002)
	C254	Guetta, V., et al., "Effects of the Antiestrogen Tamoxifen on Low-Density Lipoprotein Concentrations and Oxidation in Postmenopausal Women", The American Journal of Cardiology, 76, 1072-1073, (November 15, 1005)
	C255	Gulino, A., et al., "Heterogeneity of Binding Sites for Tamoxifen and Tamoxifen Derivatives in Estrogen Target
	<del>                                     </del>	and Nontarget Fetal Organs of Guinea Pig, Cancer Research 42, 1913-1921, (May 1982)  Guyton et al., "Inhibition of rat arterial smooth muscle cell proliferation by heparin: in vivo studies with
	C256	anticoagulant and noncoagulant heparin", Circ. Res., 46(5):625-634 (1980)
	C257	Gylling, H., et al., "Tamoxifen and Toremifene Lower Serum Cholesterol by Inhibition of Delta8-Cholesterol Conversion to Lathosterol in Women with Breast Cancer", Journal of Clinical Oncology, 13, 2900-2905, (1995)
	C258	Gylling, H., et al., "Tamoxifen Decreases Serum Cholesterol by Inhibiting Cholesterol Synthesis", Atherosclerosis, 96, 245-247, (1992)
	C259	Hafzi et al., "Differential effects of rapamycin, cyclosporine A, and FK506 on human coronary artery smooth
	C260	muscle cell proliferation and signalling", Vascul. Pharmacol., 41:167-76 (2004)  Hahn, L., et al., "The Influence of Acetylsalicylic Acid and Paracetamol on Menstrual Blood Loss in Woman With
₩		and Without an Intrauterine Contraceptive Device", Am. J. Obstet. Gnecol., 135, 393-396, (1979)
	C261	Hall, I.H., et al., "Hypolipidemic Activity of Tetrakis-mu-(trimethylamine-boranecarboxylato)-bis

		of Application No. 10/603,115
TB		(trimethylamine-carboxyborane) -dicopper (II) in Rodents and Its Effect on Lipid Metabolism", J. Pharmaceut. Sci., 73, 973-977, (1984)
	C262	Hanke, et al., Inhibition of Cellular Proliferation After Experimental Balloon Angioplasty by Low-Molecular-Weight Heparin," Circulation, Vol 85, No. 4, pp. 1548-56 (1992)
	C263	Hanson, et al., "Testing of Blood - Materials Interactions," Biomaterials Science (B.D. Ratner, Ed.), Academic
		Press, 222-238 (1996).
	C264	Hanson, S., "Device Thrombosis and Thromboembolism," Cardiovasc Pathol. 2(3) (Suppl.): 157S-165S (July-Sept. 1993)
	C265	Harpel, et al., "Plasmin Catalyzes Binding of Lipoprotein (α) to Immobilized Fibrinogen and Fibrin," Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 3847-3851 (1989)
	C266	Harrison, D.C., "Nonatherosclerotic Coronary Artery Disease", In.: Atherosclerosis and Coronary Artery Disease, V. Fuster, et al., (eds.), Lippencott-Raven Publishers, pp. 757-772, (1996)
	C267	Hayden, L.J., "Inhibitors of Gastric Lesion in the Rat", J. Pharm. Pharmac., 30, 244-246, (1978)
	C268	Hayes, D.F., et al., "Randomized Comparison of Tamoxifen and Two Separate Doses of Toremifene in Postmenopausal Patients with Metastatic Breast Cancer", Journal of Clinical Oncology, 13, 2556-2566, (Oct.
	C269	1995)   Hehrlein, C., et al., "Low-Dose Radiactive Endovascular Stents Prevent Smooth Muscle Cell Proliferation and
	(220)	Neointimal Hyperplasia in Rabbits", Circulation, 92, 1570-1575, (1995)
	C270	Hehrlein, C., et al., "Pure Beta-particle-emitting Stents Inhibit Neointima Formation in Rabbits", Circulation, 93, 641-645, (1996)
	C271	Heldin, et al., "Demonstration of an Antibody Against Platelet-derived Growth Factor," Experimental Cell Research," Vol. 136, pp. 255-261 (1981)
	C272	Heller, et al., "Preparation of Polyacetals by the Reaction of Divinyl Ethers and Polyols," J. of Polymer Science: Polymer Letters Edition, Vol. 18, pp. 293-297 (1980)
	C273	Henriksson, et al., "Hormonal Regulation of Serum Lp (a) Levels; J. Clin. Invest. Vol. 89, p. 1166-1171 (1992)
	C274	Hermann and Hirshfeld, Jr., "Clinical Use of the Palmaz-Schatz Intracoronary Stent," Futura Publishing Co.
	C275	(1993).  Hermans et al., "Prevention of restenosis after percutaneous transluminal coronary angioplasty: the search for a
		"magic bullet" American Heart Journal, 122 (1) Part, 1, 171-187, 1991  Hirata et al., "Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-
	C276	dose methotrexate". Arthritis and Reumatism, 32(9): 1065-1073, 1989
	C277	Hoff, et al., "Modification of Low Density Lipoprotein with 4-Hydroxynonenal Induces Uptake by Macrophages," Arteriosclerosis, Vol. 9, No. 4, pp. 538-549 (1989)
	C278	Hoffman, A., "Modification of Material Surfaces to Affect How They Interact with Blood, Blood in Contact with Natural and Artificial Surfaces," Leonard, E. et al., (eds), Annals of the New York Academy of Sciences, 516:96-100 (1987)
	C279	Hofmann, et al., "Enhancement of the Antiproliferative Effect of cis-Diamminedichloroplatinum(II) and Nitrogen Mustard by Inhibitors of Protein Kinase C," Int. J. Cancer, Vol. 42, pp. 382-388 (1988)
	C280	Holland, et al., "Atherogenic Levels of Low-density Lipoprotein Increase Endocytotic Activity in Cultured Human Endothelial Cells," Amer. J. of Pathology, Vol. 140, No. 3, pp. 551-558 (1992)
	C281	Holmes, et al., "Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis", Circulation, 109:634-640 (2004)
	C282	Holmes, Jr., D.R., "Remodeling Versus Smooth Muscle Cell Hyperpasia", Restenosis Summit VI, The Cleveland Clinic Foundation, 222-223, (1994)
	C283	Hoover, et al., "Inhibition of rat arterial smooth muscle cell proliferation by heparin: II. In vitro studies", Circ. Res., 47(4):578-83 (1980)
	C284	Hopfenberg, H., "Transport Through Polymers, 7 Encyclopedia of Materials Science and Engineering," (Michael B. Bever, (ed.); The MIT Press, 5141-5145 (1986)
	C285	Howell, A., et al., "New Endocrine Therapies for Breast Cancer", European Journal of Cancer, 32A, 576-588, (1996)
	C286	Huang, et al., "Rapamycins: mechanism of action and cellular resistance." Cancer Biol. Ther., 2(3):222-32 (2003)
	C287	Huang, S.S., et al., "Transforming Growth Factor Beta peptide Antagonists and Their Conversion to Partial Agonists", The Journal of Biological Chemistry, 272(43), 27155-57159, 1997
	C288	Huehns, et al., "Adventitia as a Trarget for Intravascular Local Drug Delivery", Heart, 75, 437-438 (1996)
	C289	Hughes, D.E., et al., "Estrogen Promotes Apoptosis of Murine Osteoclasts Mediated by TFG-beta", Nature Medicine, 2, 1132-1136, (1996)
	C290	Hwang et al., "Effects of Platelet-Contained Growth Factors (PDGF, EGF, IGF-1 and TGF-B) on DNA Synthesis in Porcine Aortic Smooth Muscle Cells in Culture." Exp. Cell Res., 200, 358-360 (1992)
	C291	Ishihara, et al., "Synthesis of phospholipid polymers having a urethane bond in the side chain as coating material
	C292	on segmented polyurethane and their platelet adhesion-resistant properties,"Biomaterials, 1995 16(11): 873-879  Isner, "Vascular Remodeling: Honey, I Think I Shrunk the Artery", Circulation, 89 2937-2841 (June 1994).
	C293	Jacinto and Hall, "Tor signalling in bugs, brain and brawn", Nature Rev. Mol. Cell Biol., 4:117-126 (2003)
	C294	Jampel et al., "In vitro release of hydrophobic drugs from polyanhydride disks". Ophthal Surg, 23 (11):676-680,
		NYJD: 1600258.10

			of Application No. 10/603,115
Т	'B	C295	Jande et al., "Effects of cytochalasin B and dihydrocytochalasin B on calcium transport by intestinal absorptive cells", Calcif. Tissue Int. 33, 143-151 (1981); Chem. Abs. 94 Abstract No. 189223e (1981)
Ī		C296	Jarvis, et al., "Allelopathic Agents from Parthenium hysterophorus and Baccharis megapotamica," Chemistry of Alleopathy, pp. 149-159 (1985)
	_	C297	Jarvis, et al., "Macrocylic and Other Novel Trichothecenes: Their Structure, Synthesis, and Biological
		(2)	Significance," Acc. Chem. Res. 15 pp. 338-395 (1982)
		C298	Jeng, et al., "Regulation of the levels of three transforming growth factor beta mRNAs by estrogen and their
		<b></b>	effects on the proliferation of human breast cancer cells", Mol. Cell Endocrinol., 92:115-123 (1993)
		C299	Jenkins et al., "Local Delivery of Taxol Inhibits Neointimal Regrowth Following Balloon Injury of the Rat Carotid Artery:, Circulation, 90, p. I-297, Abrstract No. 1596 (Oct. 1994)
		C300	Johnson, et al., "Coronary Atherectomy: Light Microscopic and Immunochemical Study of Excised Tissues,"
		ļ <u>.</u>	Supp. II Circulation, Vol. 78, No. 4, p. II-82 (1988)
		C301	Johnston, S.R., et al., "Changes in Estrogen Receptor, Progesterone Receptor, and ps2 Expression in Tamoxifen- resistant Human Breast Cancer", Cancer Research, 55, 3331-3338, (August 1995)
		C302	Jones, R.H., et al., "Increased Susceptibility to Metal Catalysed Oxidation of Diabetic Lens beta subL Crystallin:
			Possible Protection by Dietary Supplementation with Acetylsalicyclic Acid", Exp. Eye Res., 57, 783-790, (1993)
		C303	Jordan, A. et al., "Tubulin as a Target for Anticancer Drugs: Agents which Interact with the Mitotic Spindle", Medicinal Research Reviews, 18, 259-296, (1998)
		C304	Jordan, V. Craig, "Long-Term Tamoxifen Therapy to Control or to Prevent Breast Cancer: Laboratory Concept to
		0304	Clinical Trials," Hormones, Cell Biol. and Cancer: Perspectives and Potentials, pp. 105-123 (1988)
		C305	Jordan, V.C., et al., "A Mutant Receptor as a Mechanism of Drug Resistance to Tamoxifen Treatment", Annals
	_	-	New York Academy of Science, 761, 138-147, (1995)
		C306	Jordan, V.C., et al., "Structural Requirements for the Pharmacological Activity of Nonsteroidal Antiestrogens in Vitro", Molecular Pharmacology, 26, 272-278, (1984)
		C307	Jordan, V.C., et al., "Tamoxifen: Toxicities and Drug Resistance During the Treatment and Prevention of Breast
		ļ	Cancer", Annu. Rev. Pharmacol. Toxicol., 35, 195-211, (1995)
		C308	Joswig, B.C., et al., "Transmural Myocardial Infarction in the Absence of Coronary Arterial Luminal Narrowing in
			a Young Man with Single Coronary Arterial Anomaly", Catheterization and Cardiovascular Diagnosis, 4, 297-304,
		0200	(1978)  Jung, S.M., et al., "Platelet Cytoskeletal Protein Distributions in Two Triton-Insoluble Fractions and How They
		C309	are Affected by Stimulants and Reagents that Modify Cytoskeletal Protein Interactions" Thrombosis Research, 50
			775-787 (1988)
		C310	Kakuta, T., et al., "Differences in Compensatory Vessel Enlargement, Not Intimal Formation, Account for
	$\perp$		Restenosis After Angioplasty in the Hypercholesterolemic Rabbit Model", Circulation, 89, 2809-2815, (1994)
		C311	Kakuta, T., et al., "The Impact of Arterial Remodeling on the Chronic Lumen Size After Angioplasty in the Atherosclerotic Rabbit", JACC, Abstract No. 875-95, p. 138A, (Feb., 1994)
		C312	Kambic, et al., "Biomaterials in Artificial Organs," Chemical & Engineering News, pp. 31-48 (1986)
		C313	Kanzaki, et al., "In vivo effect of TGF-beta1: enhanced intimal thickening by administration of TGF-beta1 in rabbit arteries injured with a balloon catheter", Arterioscler. Thromb. Vasc. Biol., 15(11):1951-57 (1995)
		C314	Kariya et al., "Antiproliferative action of cyclic GMP-elevating vasodilators in cultured rabbit aortic smooth
		10215	muscle cells". Atherosclerosis, 80:143-147 (1989)  Kaski, J.C., et al., "Local Coronary Supersensitivity to Diverse Vasoconstrictive Stimuli in Patients with Variant
		C315	Angina", Circulation, 74, 1255-1265, (1996)
		C316	Kastrati et al., "Restenosis after coronary placement of various stent types," Am. J. Cardiol., 87:34-49 (2001)
		C317	Ke, H.Z., et al., "Comparative Effects of Droloxifene, Tamoxifen, and Estrogen on Bone, Serum Cholesterol, and
		C317	Uterine Histology in the Ovariectomized Rat Model", Bone, 20, 31-39, (1997)
		C318	Keen, C.L., et al., "Hypertension Induced Alterations in Copper and Zinc Metabolism: A Link to Vascular
			Disease?", In: Biology of Copper Complexes, Sorenson, J.R.J., (ed.), Humana Press, Clifton, New Jersey, 141-
		C319	153, (1987)   Kellen, J.A., "Tamaoxifen Beyond the Antiestrogen", Birkh∑user, 392 pages, (1996)
		C320	Kellen, J.A., et al., "The Effect of Toremifene on the Expression of Genes in a Rat Mammary Adenocarcinoma",
	-	<b></b>	In Vivo, 10, 511-514, (1996)
		C321	Kemp et al., "The Id Gene is Activated by Serum But is Not Required for De-differentiation in Rat Vascular Smooth Muscle Cells," Biochem. J. (Great Britain), Vol. 277, pp. 285-288 (1991)
		C322	Kemp, P.R., et al., "Cloning and Analysis of the Promoter Region of the Rat SM11-Alpha Gene", Biochem. J.,
		C323	310, 11043, (1995)   Kemp, P.R., et al., "Inhibition of PDGF BB Stimulated DNA Synthesis in Rat Aortic Vascular Smooth Muscle
		ļ	Cells by the Expression of a Truncated PDGF Receptor", FEBS Letters, 336, 119-123, (Dec., 1993)  Kemp, P.R., et. al., "ID A Dominant Negative Regulator of Skeletal Muscle Differentiation is Not Involved in
		C324	Maturation or Differentiation of Vascular Smooth Muscle Cells", FEBS Letters, 368, 81-86, (1995)
		C325	Kim, et al., "Suppression of Vascular Transforming Growth Factor-B1 and Extracellular Matrix Gene Expressions
<del>                                     </del>	+	-	by Cilazapril and Nifedipine in Hypertensive Rats", Clin. Exp. Pharmacaol. Physiol. Suppl., 1, S355, (1995)
, ,		C326	Kim, J. et al., "Production of Taxol and Related Taxanes in Taxus brevifolia Cell Cultures: Effect of Sugar", Biotechnology Letters, 17, 101-106, (Jan., 1995)
V		C327	Kingston, D.G., et al., "Synthesis and Structure-Activity Relationships of Taxol Derivatives As Anticancer
<u> </u>		Ь	NYJD: 1600258,10

		of Application No. 10/603,115
TB		Agents", In: New Trends in Natural Products Chemistry, Atta-ur-Rahman, et al., (eds.), Studies in Organic Chemistry, Vol. 26, Elsevier Science Publishers B.V., Amsterdam, 219-235, (1986)
1	C328	Kirk-Othmer, Encyclopedia of Chemical Technology, 33 <sup>rd</sup> edition, Vol. 17, 1982, John Wiley & Sons, pp. 281-310
	C329	Kirschenlohr, H.L., et al., "Adult Human Aortic Smooth Muscle Cells in Culture Produce Active TFG-Beta", Amer. J. Physiol, 265, C571-C576, (1993)
	C330	Kirschenlohr, H.L., et al., "Cultures of Proliferating Vascular Smooth Muscle Cells from Adult Human Aorta", In: Human Cell Culture, Jones, G.E., (ED.), Humana Press, Inc., 24 p. (1996)
	C331	Kirschenolohr, H.L., et al., "Proliferation of Human Aortic Vascular Smooth Muscle Cells in Culture is Modulated by Active TGF-Beta", Cardiovascular Research, 29, 848-855, (1995)
	C332	Klebe et al., "Regulation of cell motility, morphology, and growth by sulfated glycosaminoglycans", Cell Motil. Cytoskel., 6:273-281 (1986)
	C333	Klein, H.O. et al., "Experimental Investigations on a Sequential Combination Chemotherapy Protocol" J. Cancer
	C334	Res. Clin. Oncol vol 96 no.2 Jan, 1980 p 65-78  Kleinman, N.S., et al., "Prinzmetal's Angina during 5-Fluorouracil Chemotherapy", The American Journal of
	C335	Medicine, 82, 566-568, (1987)  Knabbe, C., et al., "Evidence That Transforming Growth Factor beta is a Hormonally Regulated Negative Growth
		Factor in Human Breast Cancer Cells" Cell, 48 417-428  Knabbe, C., et al., "Induction of Transforming Grown Factor-B by the Antiestrogens Droloxifene, Tamaoxifen,
	C336	and Toremifene in MCF-7 Cells", Am. J. Clin. Oncol. 14, S15-S20, (1991)
	C337	Koff, et al., "Negative Regulation of GI in Mammalian Cells: Inhibition of Cyclin E-Dependent Kinase by TGF-β, Science, Vol. 260, pp. 536-538 (1993)
	C338	Kopp, A., et al., "Transforming Growth Factor Beta2 (TGF-Beta2) Levels in Plasma of Patients with Metastatic Breast Cancer Treated with Tamoxifen", Cancer Research, 55, 4512-4515, (Oct. 15, 1995)
	C339	Kotoulas, I.G., et al., "Tamoxifen Treatment in Male Infertility. I. Effect on Spermatozoa", Fertility and Sterility, 61, 911-914, (May 1994)
	C340	Kovach, et al., "Serial Intravascular Ultrasound Studies Indicate That Chronic Recoil Is An Important Mechanism Of Restenosis Following Transcatheter Therapy," JACC Vol. 484A, Abstract 835-3 (1993)
	C341	Koyama, N., et al., "Regulation of Smooth Muscle Cells Migration by a New Autocrine Migration Factor and TGF-beta", Circulation, 84, Abstract No. 1829, II-459, (1991)
	C342	Kremer, J.M., et al., "Fish-Oil Fatty Acid Supplementation in Active Rheumatoid Arthritis", Annals of Internal Medicine, 106, 497-502, (1987)
	C343	Kreuzer, J., et al., "Lipoprotein(a) Displays Increased Accumulation Compared with Low-Density Lipoprotein in the Murine Arterial Wall", Chemistry and Physics of Lipids, 67-68, 175-190, (1990)
	C344	Kunert, et al., "Paclitaxel Inhibits Development of Restenosis Following Experimental Balloon Angioplasty in the Rabbit Carotid Artery:, European Heart Journal, 17, Abstract No. P1998, p. 368 (1996)
	C345	Kunz et al., "Defining Coronary Restenosis Newer Clinical and Angiographic Paradigms". Circulation, 88 1310-1323 (September 1993)
	C346	Kunz et al., "Sustained Dilation and Inhibition of Restenosis in a Pig Femoral Atery Injury Model". Circulation, 90, p I-297, Abstract NO. 1598 (October 1994)
	C347	Kunz et alk., "Inhibition of Microfilament Reorganization Following Balloon Angioplasty Decreases Extent of
		Geometric Remodeling in Restenosis, "J. of Amer. Coll. of Cardiology, AMerican College of Geometric Cardiology 44th Annual Scientific Session, Abstract No. 122292. (March 19-22, 1995)
	C348	Kunz, L.L., et al., "Efficacy of Cytochalasin B in Inhibiting Coronary Restenosis Caused by Chronic Remodeling After Balloon Trauma in Swine", Journal of the American College of Cardiology, Supplement A., Abstract No. 984-23, p. 302, (Mar. 1995)
	C349	Kuramochi, H., "Conformational Studies and Electronic Structures of Tamoxifen and Toremifene and Their Allylic Carbocations Proposed as Reactive Intermediates Leading to DNA Adduct Formation", J. Med. Chem., 39,
	C350	2877-2886, (1996)  Kuzana, S., et al., "Effects of Some Anti-Rheumatic Agents on Copper-Catalyzed Thermal Aggregation of
	C351	Gamma Globulin", Agents and Actions, 9 375-380, (1979)  L.C., Palmaz et. al., Expandable Intraluminal Graft: A Preliminary Study, Radiology 1985;1:73-77.
	C352	Labhsetwar et al., "Nanoparticles for site specific delivery of U-86983 in restenosis on pig coronary arteries," Proc
	C353	Intern. Symp. Control. Rel. Bioact. Mater. 22, 182-183 (1995).   LaFont, et al., "Post-angioplasty Restenosis In The Atherosclerotic Rabbit: Proliferative Response Or Chronic
	C354	Constriction?," Circulation, Vol. 88, I-521, Abstract 2806 (1993)  Laird, J., et al., "Inhibition of Neointimal Proliferation with Low-dose Irradiation from a Beta-particle-emitting
	C355	Stent", Circulation, 93, 529-536, (1996)  Lambert et al., "A new method for arterial drug delivery via removable stent". JACC, 21(2):483A, #834-2, 1992
	C356	Lambert, et al., "Local Drug Delivery Catheters: Functional Comparison of Porous and Microporous Designs," Coronary Artery Disease, Vol. 4, No. 5, pp. 469-475 (1993)
	C357	Langbein, W., "Too Many Drugs, Too Little Value in CV Conditions", In Vivo, 14-20, (June, 1995)
	C358	Lange, R.A., et al., "Cocaine-Induced Coronary-Artery Vasoconstriction", The New England Journal of Medicine, 321, 1557-1562, (1989)
V	C359	Lange, R.L., et al., "Nonatheromatous Ischemic Heart Disease following Withdrawal from Chronic Industrial

	<del> </del>	of Application No. 10/603,115
TB		Nitroglycerin Exposure", Circulation, 46, 666-678, (1972)
	C360	Langer, R., "New Methods of Drug Delivery", Science, Vol. 249, 28.09 1990, pp. 1527-1533
	C361	Langer, R., "Polymeric Delivery Systems for Controlled Drug Release", Chem. Eng. Communi. 6:1-48 (1980)
	C362	Law et al., "Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells", Mol. Cell. Biol., 22:8184-8198 (2002)
	C363	Lawn, R.M., et al., "Feedback Mechanism of Focal Vascular Lesion Formation in Transgenic Apolipoprotein(a) Mice", The Journal of Biological Chemistry, 271, 31367-31371, (1996)
	C364	Lazier, C.B., et al., "Comparison of the Effects of Tamoxifen and of a Tamoxifen Analogue that Does Not Bind the Estrogen Receptor on Serum Lipid Profiles in the Cockerel", Biochem. Cell Biol., 68, 210-217, (1990)
	C365	LC. Palmaz et al., Expandable Intraluminal Vascular Graft: A Feasibility Study, Surgery 1986 Feb; 199(2): 199-205.
	C366	Lefer, Allen M., "Role of Transforming Growth Factor β in Cardioprotection of the Ischemic-Reperfused Myocardium," Growth Factors and the Cardiovascular System, Chapter 14 (Cummins, P. ed.), Kluwer Academic Publishers, pp. 249-260 (1993)
	C367	Lefer, et al., "Mechanism of the Cardioprotective Effect of Transforming Growth Factor β <sub>1</sub> , in Feline Myocardial Ischemia and Reperfusion," PNAS (USA), Vol. 90, pp. 1018-22 (1993)
	C368	Lefer, et al., "Mediation of Cardioprotection by Transforming Growth Factor-β," Science, Vol. 249, pp. 61-64 (1990)
	C369	Lehmann, K. et al., "Effect of cilazapril on the proliferative response after vascular damage", J. of Cardiovascular Pharmacology, 22 (Suppl. 4), S19-24, (1993)
	C370	Lehmann-Bruinsma, et al., "Transforming Growth Factor B2 (TGF-B) Suppression of Smooth Muscle Cell (SMC) Proliferation After Balloon Angioplasty of Rat Carotid Arteries", Clin. Res. 42, Abstract No. 4A, (February 9-12, 1994)
	C371	Leroux et al., "Internalization of poly(D L-lactic acid) nanoparticles by isolated human leukocytes and analysis of plasma proteins adsorbed onto the particles," J. Biomed. Mater. Res., 28, 471-481 (1994)
	C372	Leroux, et al., "New Approach for the Preparation of Nanoparticles by an Emulsification-Diffusion Method", Eur. J. Pharm. Biopharm, 41, 14-18, (1995)
	C373	Levy, "Drug Release from Submicronized O/W Emulsion: A New In Vitro Kinetic Evaluation Model", Intl. J. Pharmaceut. ,66, 29-37 (1990)
	C374	Levy, et al., "Strategies for Treating Arterial Restenosis Using Polymeric Controlled Release Implants," Chemical Abstracts, 121, 580: Abstract No. 263625g (1994)
	C375	Levy, R.J., et al., "Strategies for Treating Arterial Restonosis Using Polymeric Controlled Release Implants", In: Biotechnology and Bioactive Polymers, Proceedings of an American Chemical Society Symposium, Gebelein, C.G., (ed.), Plenum Press, New York, 259-268, (1994)
	C376	Li, et al., "Structure and Dynamics of Microemulsions which Mimic the Lipid Phase of Low-Density Lipoproteins", Biochimica et Biophysica Acta, 1042, 42-50 (1990)
	C377	Liau and Chan, "Regulation of extracellular matrix RNA levels in cultured smooth muscle cells: relationship to cellular quiescence", J. Cell Biol., 264:10315-10320 (1989)
	C378	Liaw, et al., "Osteopontin Promotes Vascular Cell Adhesion and Spreading and Is Chemotactic for Smooth Muscle Cells In Vitro," Cir. Res. Vol. 74, No. 2, pp. 214-224 (1994)
	C379	Lichtlen et al., "Retardation of angiographic progression of coronary artery disease by nifedipine", Lancet, 335:1109-1113 (1990)
	C380	Lin, et al., "Expression Cloning of the TGF-β Type II Receptor, a Functional Transmembrane Serine/Threonine Kinase," Cell. Vol. 68, pp. 775-785 (1992)
	C381	Lincoff et al., "Local Drug Delivery for the Prevention of Restenosis" Circulation, 90 2070-2084 (October 1994)
	C382	Lindkaer-Jensen, S., et al., "Inhibition of Salicylate and Lithium Absorption in the Human Intestine by Copper Sulfate", Arch. Toxicol., 35, 175-179, (1976)
	C383	Lindner, "Vascular repair processes mediated by transforming growth factor-beta, Z Kardiol", 90 Suppl 3:17-22 (2001)
	C384	Linn, et al., "Microemulsion for Intradermal Delivery of Cetyl Alcohol and Octyl Dimethyl Paba", Drug Development and Industrial Pharmacy, 16, 899-920
	C385	Lipold, B.C., "Retardarzneiformen" in E. Numberg, Hagers Handbuch der pharmazeutischen Praxis, Vol. 2, Springer-Verlag Berlin Heidelberg New York, 5 <sup>th</sup> edition, 1991 pp. 832-840
	C386	Lippman and Mathews, "Heparins: varying effects on cell proliferation in vitro and lack of correlation with anticoagulant activity", Fed. Proc., 36:55-59 (1977)
	C387	Lipski, et al., "Cytochalasin B: Preparation, Analysis in Tissue Extracts, and Pharmacokinetics After Intraperitoneal Bolus Administration In Mice," Analytical Biochem., Vol. 161, pp. 332-340 (1987)
	C388	Liu et al., "Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit", Circulation, 81(3): 1089-1093 (1990)
	C389	Liu, et al., "Restenosis After Coronary Angioplasty - Potential Biologic Determinants and Role of Intimal Hyperplasia," Circulation, Vol. 79, No. 6, pp. 1374-87 (1989)
	C390	Lopez-Anaya, A., et al., "Pharmacokinetics and Pharmacodynamics in Copper Deficiency 1", Biological Trace Element Research, 40, 161-176, (1994)
₩	C391	Lopez-Casillas, et al., "Beta-glycan Presents Ligand to the TGFBeta Signaling Receptor", Cell, 73, 1435-1444,

		(1.1.2 1.002)
TB		(July 2, 1993)
	C392	Loser, R., et al., "In Vivo and in Vitro Antiestrogenic Action of 3-Hydroxytamoxifen, Tamoxifen and 4-Hydroxytamoxifen", Eur. J. Cancer Clin. Oncol., 21, 985-990, (1985)
	C393	Love, et al., "Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women," Annals of Internal Medicine, Vol. 115, No. 11, pp. 860-864 (1991)
	C394	Love, et al., "Effects of Tamoxifen Therapy on Lipid and Lipoprotein Levels in Postmenopausal Patients with Node-Negative Breast Cancer," J. of the National Cancer Institute, Vol. 82, No. 16, pp. 1327-32 (1990)
	C395	Lowe, et al., "Coronary In-Stent Restenosis: Current Status and Future Strategies", Journal of the American College of Cardiology, 1992, Vol. 39 No. 2, pp. 183-193.
	C396	Luan et al., "Rapamycin is an effective inhibitor of human renal cancer metastasis", Kidney Int., 63:917-926
	C397	Lucas, C., et al., "The Authorrine Production of Transforming Growth Factor-B1 During Lymphocyte
	C398	Activation", The Journal of Immunology, 145(5), 1415-1422, (1990)  Luo, H. et al., "Chronic Vessel Constriction is an Important Mechanism of Restenosis After Balloon Angioplasty:
	C399	An Intravascular Ultrasound Analysis", Circulation, 90, 67 Scientific Sessions, Abstract No. 0318, p. 1-61, (1994) Luostarinen, R., et al., "Effect of Dietary Fish Oil Supplemented with Different Doses of Vitamin E on Neutrophil
	C400	Chemotaxis in Healthy Volunteers", Nutrition Research, 12, 1419-1430, (1992)  Lutgens et al., "Transforming growth factor-beta mediates balance between inflammation and fibrosis during
	C401	plaque progression", Arterioscler. Thromb. Vasc. Biol., 22:975-982 (2002)  Lyons et al., "Mechanism of activation of latent recombinant transforming growth factor beta1 by plasmin", J.
		Cell. Biol., 110:1361-1367 (1990)  Macander et al., "Balloon Angioplasty for Treatment of In-Stent Restenosis: Feasibility, Safety, and Efficacy",
	C402	Catheterization and Cardiovascular Diagnosis, 32 125-131 (1994)
	C403	Madri et al., "Endothelial cell behavior after denudation injury is modulated by transforming growth factor-betal and fibronectin", Lab. Invest., 60:755-764 (1989)
	C404	Magarian, "The Medicinal Chemistry of Nonsteroidal Antiestrogens: A Review", Current Medicinal Chemistry, 1, 61-104, (1994)
	C405	Maione, Theodore E. and Sharpe, Richard J. "Development of angiogenesis inhibitors for clinical applications" TiPS- Nov. 1990 [Vol. 11]
	C406	Majack, "Beta-type transforming growth factor specifies organizational behavior in vascular smooth muscle cell cultures", J. Cell Biol., 105:465-471 (1987)
	C407	Majack, R.A., et al., "Role of PDGF-A Expression in the Control of Vascular Smooth Muscle Cell Growth by Transforming Growth Factor-B", The Journal of Cell Biology, 111, 239-247, (1990)
	C408	Majesky, M.W., et al., "Production of Transforming Growth Factor betal During Repair of Arterial Injury", J. Clin. Invest., 88, 904-910, (1991)
	C409	Malcolmson, et al., "A Comparison Between Nonionic Micelles and Microemulsions as a Means of Incorporating the Poorly Water Soluble Drug Diazepam", J. Pharm. Pharmacol, 42 6p, (1990)
	C410	Mambetisaeva, E.T., et al. "Effect of New Synthetic Cholesterol Derivatives on Cholesterol Metabolism in Cultured Rabbit Hepatocytes", Biokhimiya (Russia), 58, Translation, Plenum Publishing Corporation, 1126-1132 (1993)
	C411	Manasek, et al., "The Sensitivity of Developing Cardiac Myofibrils to Cytochalasin-B, PNAS (USA), Vol. 69, No. 2, pp. 308-312 (1972)
	C412	Mang, Tien-Dung Duc, "Distribution to Normal and Tumor Tissues of Cytochalasin B After Intravenous Administration in Mice," Thesis Submitted for Honors B.S. in Biology, Syracuse University
	C413	Manucci, P.M., et al., "Effect of Tamoxifen on Measurements of Hemostatis in Healthy Women", Arch. Intern. Med., 156, 1806-1810, (1996)
	C414	Marx and Marks, "Bench to Bedside: The development of rapamycin and its application to stent restenosis", Circulation 104:852-55 (2001)
	C415	Marx, "CMV-p.53 Interaction May Help Explain Clogged Arteries", Science, 265, 320, (Jul 1994)
	C416	Marzocchi, A., et al., "Restenosis after Coronary Angioplasty: It's Pathogenesis and Prevention," Cardiologia, 36 309-320 (December, 1991) English Abstract only, reported in Medline, Accession No. 93046311
	C417	Massague and Wotton, "Transcriptional control by the TGF-beta/Smad signaling system", EMBO J., 19(8):1745-54 (2000)
	C418	Massague et al., "Type beta transforming growth factor is an inhibitor' of myogenic differentiation", Proc, Natl. Acad. Sci., 83:8206-8210 (1986)
	C419	Massagué, Joan, "The Transforming Growth Factor-B; Family", Annu. Rev. Cell Biol. Vol. 6, pp. 597-641 (1990)
	C420	Massague,"Subunit structure of a high-affinity receptor for' type beta-transforming growth factor: evidence for a disulfide-linked glycosylated receptor complex", J. Biol. Chem., 260(11):7059-7066 (1985)
	C421	McAuslan, B.R., et al., "Cellular and Molecular Mechanisms in Angiogenesis", Trans. Ophthal. Soc. U.K., 100, 354-358, (1980)
	C422	McCaffrey et al, "Genomic instability in the type II TGF-b1 receptor gene in atherosclerotic and restenotic vascular cells," J Clin Invest, 100:2182-2188 (1997)
$\sqrt{}$	C423	McCaffrey et al., "Aging and arteriosclerosis: the increased proliferation of arterial smooth muscle cells isolated from old rats is associated with increased platelet-derived growth factor-like activity," J. Exp. Med., 167:163-174
		(1988)

TB	C424	McCaffrey et al., "Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1", J. Clin. Invest., 96:2667-2675 (1995)
1	C425	McCaffrey, "TGF-betas and TGF-beta receptors in atherosclerosis," Cytokine and Growth Factor Rev., 11:103-114 (2000)
	C426	McCaffrey, et al., "Transforming Growth Factor; β Activity is Potentiated by Heparin Via Dissociation of the Transforming Growth FactMacroglobulin Inactive Complex," The J. of Cell Biology, Vol. 109, pp. 441-448 (1989)
	C427	McCaffrey, T.A., et al., "Fucoidan is a Non-Anticoagulant Inhibitor of Intimal Hyperplasia", Biochemical and Biophysical Research Communications, 184, 773-781, (1992)
	C428	McCague, R., et al., "An Efficient, Large Scale Synthesis of Idoxifene ((E)-1(4- (2- (N-pyrrolidino) ethoxyl) -1- (4-iodophenyl) -2-phenyl-1-butene)", Organic Preparations and Proc. Int., 26, 343-346, (1994)
	C429	McCague, R., et al., "Synthesis of 4-Stannylated Tamoxifen Analogues: Useful Precursors to Radiolabelled Idoxifene and Axiridinyl 4-Iodotamoxifen.", J. Labelled Compounds and Pharmaceuticals, 34, 297-302, (1994)
	C430	McCarroll, et al., "Preliminary Studies on the Regulation of Secretion of Latent Transforming Growth Factor-β (TGF-β) by Endothelial Cells in Culture, Clin. Chem. Vol. 36, No. 6, pp. 1152 (1990) Abstract No. 0934
	C431	McClean, et al., "cDNA sequence of human apolipoprotein (a) is homologous to plasminogen", Nature, 330, 132-137 (1987), 132-137, (1987)
	C432	McCormick, et al., "Retinoid-Tamoxifen Interaction in Mammary Cancer Chemoprevention," Carcinogenesis, Vol. 7, No. 2, pp. 193-196 (1986)
	C433	McDonald, C.C., et al., "Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial", BMJ, 311, 977-980, (October 14, 1995)
	C434	McDonald, et al., "Fatal Myocardial Infarction in the Scottish Adjuvant Tamoxifen Trial," BMJ, Vol. 303 pp. 435-437 (1991)
	C435	McDonnell, D.P., et al., "Analysis of Estrogen Receptor Function in Vitro Reveals Three Distinct Classes of Anti estrogens", Molecular Endocrinology, 9, 65-669, (June 1995)
	C436	McLaughlin, C.S., et al., "Inhibition of Protein Synthesis by Trichothecenes", In: Mycotoxins in Human and Animal Health, Pathotox Publishers, Inc., 263-273, (1977)
	C437	McMurray et at., "A standardised method of culturing aortic explants, suitable for' the study of factors affecting the phenotypic modulation, migration and proliferation of aortic smooth muscle cells," Atherosclerosis, 86:227-237 (1991)
	C438	McQuiggan, James Daniel: "Tissue Distribution of Cytochalasin B After Intraperitoneal Bolus and Microencapsulated Injection in Mice and its Effect on β-N-Acetylglucosaminidase Activity in Cultured B16-BL6 Melanoma Cells," Thesis Submitted in partial fulfillment of the requirements for the degree of Master of Science in Biology in the Graduate School of Syracuse University, published Syracuse University, Biology Dept. (1988)
	C439	Meiser et al., "Effectsof Cyclosporin, Fk506, and Rapamycin on Graft-Vessel Disease", The Lancet, 338, 1297-1298 (1991)
	C440	Merck Index,, (Susan Budavari et al, ed.) 1989, p 1435
	C441	Merrilees and Scott, "Antisense S-oligonucleotide against transforming growth factor-beta 1 inhibits proteoglycan synthesis in arterial wall," L Vase. Res. 31:322-329 (1994)
	C442	Merrilees et al., "Effect of TGF-beta(1) antisense S-oligonucleotide on synthesis and accumulation of matrix proteoglycans in balloon catheter-injured neointima of rabbit carotid arteries, 3". Vasc. Res. 37:50-60 (2000)
	C443	Merrilees, et al., "Synthesis of TGF-β <sub>1</sub> by Vascular Endothelial Cells is Correlated with Cell Spreading," J. Vasc. Res., Vol. 29, pp. 376-384 (1992)
	C444	Metcalfe et al., "Calcium and cell proliferation," Br. Med., Bull., 42(4):405-4t2 (1986)
	C445	Metcalfe, et al., "Protein Markers of Lesion Development in the Vessels of Transgenic Apo(a) Mice" Inflammation, Growth Regulatory Molecules & Atherosclerosis, J. Cellular Biochem., SUpplement 18A, p 208, Abstract No. E212 (1994)
	C446	Metcalfe, et al., "Transforming Growth Factor-B and the Protection From Cardiovascular Injury Hypothesis.
	C447	Meyer, S.C., "Functionalized Cytochalasins for Potential Biotechnology Transfer", Ph. D. Thesis (Selected Pages) Syracuse University, New York, 13 p., (May, 1994)
	C448	Michael N. Helmus, "Materials Selection, Chapter 2," Encyclopedic Handbook of Biomaterials and Bioengineering, Part A: Materials, Vol. 1 (1995)
	C449	Michael N. Helmus, "Materials Selection, Chapter 6, Cardiovsc. Pathol. 2(3)(Suppl.):53s-71s (July-Sept. 1993)
	C450	Michael N. Helmus, "Materials Selecton for Medical Devices," Spectrum, 1-21, (July 30, 1993)
	C451	Michael N. Helmus, "Opportunities for Biomaterials," DH Reports, (February 1995)
<del>-   -  </del>	C452	Michael N. Helmus, "Technological Advances in Thromboresistant Materials," Spectrum, 1-13 (June 19, 1990)
	C453	Michael N. Helmus, "Thromboresistant Biomaterials: Technical Developments and Applications," Spectrum, (Sept. 12, 1990)
	C454	Middlebrook, et al., "Specific Association of T-2 Toxin with Mammalian Cells," Biochem. Pharmacology, Vol. 38, No. 18, pp. 3093-3102 (1989)
<b>\</b> //	C455	Middlebrook, J.L., et al., "Binding of T-2 Toxin to Eukaryotic Cell Ribosomes", Biochemical Pharmacology, 38
<b>*</b>		33110, (1989)

		of Application No. 10/603,115
ТВ	C456	Milner, M.R., et al., "Usefulness of Fish Oil Supplements in Preventing Clinical Evidence of Restenosis After Percutaneous Transluminal Coronary Angioplasty", Am. J. Cardiol., 64, 294-299 (1989)
	C457	Mintz, G.S., et al., "Chronic Compensatory Arterial Dilation Following Coronary Angioplasty: An Intravascular Ultrasound Study", JACC, Abstract No. 875-97, p. 138A, (Feb., 1994)
	C458	Mintz, G.S., et al., "Geometric Remodeling is the Predominant Mechanism of Clinical Restenosis After Coronary Angioplasty", JACC, Abstract No. 875-42, p. 138A, (Feb., 1994)
	C459	Mintz, G.S., et al., "Mechanisms of Late Arterial Response to Transcatheter Therapy: A Serial Quantitative Angiographic and Intravascular Ultrasound Study", Circulation, 90, Abstract No. 117, p. I-24, (Oct., 1994)
	C460	Mirjalili, N. et al., "Methyl Jasmonate Induced Production of Taxol in Suspension Cultures of Taxus Cuspidata: Ethylene Interaction and Induction Models", Biotechnol. Prog., 12, 110-118, (1996)
	C461	Mirjalili, N., et al., "Gas Phase Composition Effects on Suspension Cultures of Taxus cuspidata", Biotechnology and Bioengineering, 48, 123-132, (1995)
	C462	Mitchell, L.L., et al., "Copper Deficiency Depresses Rat Aortae Superoxide Dismutase Activity and Prostacyclin Synthesis", Prostaglandins, 35, 977-986, (1988)
	C463	Molling, K., "Naked DNA for Vaccine or Therapy", J. Mol. Med., 75, 242-246, (1997)
	C464	Moorthy, B., et al., "Tamoxifen Metabolic Activation: Comparison of DNA Abducts Formed by Microsomal and Chemical Activation of Tamoxifen and 4-Hydroxytamoxifen with DNA Abducts Formed in Vivo", Cancer Research, 56, 53-57, (Jan. 1, 1996)
	C465	More et al., "A Targeted Antithrobotic Conjugate with Antiplatelet and Fibrinolytic Properties which reduces in vivo Thrombus Formation", Cardiovascular Research, 27, 2200-2204 (1993).
	C466	Morisaki, et al., "Effects of Transforming Growth Factor β on Growth of Aortic Smooth Muscle Cells," Atherosclerosis, Vol. 88, pp. 227-234 (1991)
	C467	Morris et al., "Rapamycin (sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells," Transplant Proc, 27:430-31 (1995)
	C468	Morris, R.E., "Rapamycins: Antifungal, Antitumor, Antiproliferative, and Immunosuppressive Macrolides", Transplantation Reviews, 6, 39-87, (1992)
	C469	Morris, R.E., et al., "Immunosuppressive Effects of the Morpholinoethyl Ester of Mycophenolic Acid (RS-61443) in Rat and Nonhuman Primate Recipients of Heart Allografts", Transplantation Proceedings, 23, 19-25, (1991)
	C470	Mosedale and Grainger, "An antibody present in normal human serum inhibits the binding of cytokines to their receptors in an in vitro system," Biochem J., 343:125-133 (1999)
	C471	Mosedale, D.E. University of Cambridge Ph.D. Thesis, Differentiated state of smooth muscle and its relationship to TGF-β in vivo, DJG 005652-005910 (1998) and all references therein
	C472	Mosedale, D.E., et al., "Transforming Growth Factor-beta is Correlated with Smooth Muscle Cell Differentiation in Vivo", Circulation, 90, 67 <sup>th</sup> Scientific Session, Abstract No. 1590, p. I-296, (Oct., 1994)
	C473	Moses and Langer "Inhibitors of angiogenesis". Bio/Technology. 9:630-634, 1991
	C474	Murphy, C.S., et al., "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen", J. Steroid Biochem, 34, 1-6 (1989)
	C475	Murphy, C.S., et al., "Structure-Activity Relationships of Nonisomerizable Derivatives of Tamoxifen: Importance of Hydroxyl Group and Side Chain Positioning for Biological Activity", Molecular Pharmacology, 39, 421-428, (1991)
	C476	Murphy, L.C., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Proliferation in Vitro", Endocrinology, 116, 1071-1078, (1985)
	C477	Myer, R.O, et al., "Performance and Carcass Characteristics of Swine When Fed Diets Containing Canola Oil and Added Copper to Alter the Unsaturated: Saturated Ration of Pork Fat", J. Anim. Sci., 70, 1417-1423, (1992)
	C478	Nabel, "Recombinant Gene Expression in Vivo Within Endothelial Cells of the Arterial Wall", Science, 244, 1342-1344 (1983)
	C479	Nabel, E.G., et al., "Direct Transfer of Transforming Growth Factor Beta 1 Group Into Arteries Stimulates Fibrocellular Hyperplasia", Proc. Natl. Acad. Sci. USA, 90, 10759-10763, (1993)
	C480	Nagakawa, Y., et al., "Effect of Eicosapentaenoic Acid on the Platelet Aggregation and Composition of Fatty Acid in Man", Atherosclerosis, 47, 71-75, (1983)
	C481	Naito, et al., "Vascular Endothelial Cell Migration In Vitro Roles of Cyclic Nucleotides, Calcium Ion and Cytoskeletal System," Artery, Vol. 17(1), pp. 21-31 (1989)
	C482	Nakagawa, et al., "A Case of Acute Myocardinal Infarction Intracoronary Arteries Due To Hormone Therapy.", Angiology, 45, 333-338, (May 1994)
	C483	Nakano, "Glucocorticoid Inhibits Thromin-Induced Expression of Platelet-Derived Growth Factor A-chain and Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Human Aortic Smooth Muscle Cells:, The Journal of Biological Ch emistry, 268, 22941-22947 (1993)
	C484	Nakao, et al., "Calcium Dependency of Aortic Smooth Muscle Cell Migration Induced by 12-L-Hydroxy-5,8,10,14-eicosatetraenoic Acid," Atherosclerosis, Vol. 46, pp. 309-319 (1983)
	C485	Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Securities, Equity Research Medical Technology, 10 p., (Mar. 3, 1995)
	C486	Nayfield, S.G., et al., "Tamoxifen-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14(3), 1018-1026, (1996)
V	C487	Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vascular

		of Application No. 10/603,115
TB		restenosis: Analysis of 62 patients with one or more episode of restenosis," Cardiovasc. Pathol., 3:57-64 (1994)
ı	C488	Nikol, et al., "Expression of Transforming Growth Factor β <sub>1</sub> is Increased in Human Vascular Restenosis Lesions," J. Clin. Invest., Vol. 90, pp. 1582-92 (1992)
	C489	Nunes, et al., "Vitamins C and E Improve the Response to Coronary Balloon Injury In the Pig: Effect of Vascular Remodeling," Circulation, Vol. 88, No. 4, Part 2, p. I-372 (1993)
	C490	O'Brien, et al., "Osteopontin mRNA and Protein are Overexpressed in Human Coronary Atherectomy Specimens: Clues to Lesion Calcification," Cir. Vol. 88, p. 1-619, Abstracts from the 66th Scientific Sessions (1993)
	C491	O'Connor-McCourt, et al., "Latent Transforming Growth Factor β in Serum: A Specific Complex with 2- Macroglobulin," The Journal of biological Chemistry, Vol. 262, No. 29, pp. 14090-14099 (1987)
	C492	O'Leary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and Its Used as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996)
	C493	Ohmi, et al., "Effect of K252a, A Protein Kinase Inhibitor, on the Proliferation of Vascular Smooth Muscle Cells," Biochemical and Biophysical Research Communications, Vol. 173, No. 3, p. 976-981 (1990)
	C494	Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Afterial Injury", Science, 265, 781-784, (August 5, 1994)
	C495	O-Keefe Jr. et al., "Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty". JACC, 19(7): 1597-1600, 1992
	C496	Okuyyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activity and Possible Opoid Receptor Activation", Agents and Actions, 21, 130-144, (1987)
	C497	Oliveira, et al., "Isolation and Characterization of Smooth Muscle Cell Membranes," Biochimica et Biophysica Acta. Vol. 332, pp. 221-232 (1974)
	C498	Opherk, D., et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989)
	C499	Orlov, S.N., et al., "Altered beta-Adrenergic Regulation of Na-K-Cl Cotransport in Cultured Smooth Muscle Cells Form the Aorta of Spontaneously Hypertensive Rats", American Journal of Hypertension, 8, 739-747, (1995)
	C500	Osborne, et al., "Microemulsions as Topical Drug Delivery Vehicles: In Vitro Trandermal Studies of a Model Hydrophilic Drug", J. Pharm. Pharmacol., 43, 451-454 (1991).
	C501	Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liver DNA of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996)
	C502	Osipow, "Transparent Emulsion" J. Soc. Cosmetic Chemists, 277-285 (1963).
	C503	Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertrophy in Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988)
	C504	Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis", Biochem Mol. Biol. Intern, 35, 117-124, (1995)
	C505	Palmaz et al., "Balloon Expandable Intraluminal Grafting of Normal and Abnormal Renal Arteries: Experimental Study," Radiology 1986 Nov; 161 (P):40-41 Abstract 85.
	C506	Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertension," A JR 1986 Dee; 147:1251-54.
	C507	Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. J. Roentgenol. 1985;145:821-825.
	C508	Palmaz et al., "Expandable Intraluminal Grafting in Atherosclerotic Rabbit Aortas," Radiology 1985 Nov; 157(P):66 Abs 130.
	C509	Palmaz et al., "Intravascular Stents", Advances in Vascular Surgery, 1, 107-135 (1993).
	C510	Palmaz et al., "Normal and Stenotic Renal Arteries: Experimental Balloon-expandable Intraluminal Stenting," Radiology 1987 Sept; 164(3):705-708.
	C511	Palmaz et al., "Removable Biliary Endoprosthesis," Am, J. Roentgenol. 1983;140(4):812-4.
	C512	Palmaz, et al., "Expandable Intrahepatic Portocaval Shunt Stents in Dogs with Chronic Portal Hypertension," American Roentgen Ray Soc'y 1986 Annual Meeting, Washington, D.C., (BT 000079) (April 13-18, 1986).
	C513	Palmaz, et al., "Intravascular Stents: Basic Physical and Biological Properties, Endoluminal Treatment: The Different Techniques.". Editors Michel Henry, Max Amor, Edward B. Diethrich and Barry Katzen. Published by Springer Verlag; 4:149-158 (1997).
	C514	Palmaz, J.C. "Expandable Intraluminal Graft: A Preliminary Study," Radiology 1984 Nov;153(P):329 Abs. 993.
	C515	Palmaz, J.C., "Balloon-Expandable Intravascular Stent", Am. J. of Radiol. 150:1263-1269 (1988)
	C516	Pandey, B.L., et al., "A Study of the Effects of Tamrabhasma, an Indigenous Preparation of Copper on Experimental Gastric Ulcers and Secretion", Indian Journal of Experimental Biology, 21, 258-264, (1983)
	C517	Pardee, A.B., et al., "Control of Cell Proliferation", Cancer, 39, 2747-2754, (1977)
	C518	Pardoll, D., et al., "Exposing the Immunology of Naked DNA Vaccines", Immunity, 3, 165-169, (1995)
	C519	Parthasatathy, S., et al., "A Role for Endothelial Cell Lipoxygenase in the Oxidative Modification of Low Density Lipoprotein", Proc. Nat'l Acad. Sci., USA, 86, 1046-1050, (1989)
	C520	Pathak, et al., "Enhanced Stability of Physostigmine Salicylate in Submicron o/w Emulsion", International Journal of Pharmaceutics, 65, 1690175 (1990)
V	C521	Pedron, N. et al., "The Effect of Acetylsalicyclic Acid on Menstrual Blood Loss in Women with IUDs", Contraception, 36, 295-303, (1987)
		NYJD: 1600258 10

		of Application No. 10/603,115
TB	C522	Peng et al., "The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation," Mol. Cell Biol., 22:5575-84 (2002)
1	C523	Pennisi, E., "Drug's Link to Genes Reveals Estrogen's Many Sides", Science, 273, 1171, (Aug. 30, 1996)
	C524	Peress, N.S., et al., "Differential Expression of TGF-B1, 2 and 3 Isotypes in Alzheimer's Disease: A Comparative Immunohistochemical Study with Cerebral Infarction, Aged Human and Mouse Control Brains", Journal of Neuropathology and Experimental Neurology, 54, 802-811, (November 1995)
	C525	Peress, N.S., et al., "Glial Transforming Growth Factor (TGF) -B Isotypes in Multiple Sclerosis: Differential Glial Expression of TGF- B1, 2, and 3 Isotypes in Multiple Sclerosis", Journal of Neuroimmunology, 71, 115-123, (1996)
	C526	Perez, J.R., et al., "Regulation of Adhesion and Growth of Fibrosarcoma Cells by NF - kb RelA Involves Transforming Growth Factor Beta", Molecular and Cellular Biology, 14, 5326-5332, (1994)
	C527	Pinto, H.C., et al., "Tamoxifen-associated Steatohepatitis C Report of Three Cases", Journal of Hepatology, 23, 95-97, (1995)
	C528	Podzimek, et al., "O/W Microemulsions", J. Dispersion Science and Technology, I, 341-359 (1980)
	C529	Popma, et al., "Factors Influencing Restenosis After Coronary Angioplasty", The Amer. J. of Med. Vol. 88, pp. 1-16N - 1-24N (1990)
	C530	Post et al., "The Relative Importance of Arterial Remodeling Compared With Intimal Hyerplasia in Lumen Renarrowing After Balloon Angioplasty" Circulation 89, 2816-2821 (June 1994)
	C531	Post, et al., "Restenosis Is Partly Due To Intimal Hyperplasia And Partly To Remodeling Of The Injured Arterial Wall," European Heart J., Vol. 14, p. 201, Abstract P1164 (1993)
	C532	Post, et al., "Which Part Of The Angiographic Diameter Reduction After Balloon Dilation Is Due To Intimal Hyperplasia?", JACC, Vol. 21, 36A, Abstract, 851-95 (1993)
	C533	Potter et al., "A mechanism hypothesis for DNA adduct formation following hepatic oxidative metabolism," Carcinogenesis, 15, 439-442 (1994)
	C534	Pouton, C.W., "Self-Emulsifying Drug Delivery Systems: Assessment of the Efficiency of Emulsification", International Journal of Pharmaceutics, 27, 335-348, (1985)
	C535	Powell et al., "Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury," Science, 245:186-188 (1989)
	C536	Powell et al., "Suppression of the Vascular Response to Injury: The Role of Angiotensin-Converting Enzyme Inhibitors", JACC, 17, 137B-142B (1991).
	C537	Presentation at The Society of CV & Interventional Radiology's Twelfth Annual Course On "Diagnostic Angiography and Interventional Radiology." Includes: "The Current Status of Vascular Prostheses" by Julio
	C538	Palmaz at 118-120 (March 23 - 26 1987).  Program and abstracts of the Seventh International Conference on the Adjuvant Therapy of Cancer, held in
	C539	Tuscon, Arizona on March 10-13, 1993  Pupita, G., et al., "Myocardial Ischemia Caused by Distal Coronary-Artery Constriction in Stable Angina  Pectoris", The New England Journal of Medicine, 323, 514-520, (1990)
	C540	Rainsford, K.D., et al., "Concerning the Merits of Copper Aspirin as a Potential Anti-Inflammatory Drug", J. Pharm. Pharmac., 28, 83-86, (1976)
	C541	Rainsford, K.D., et al., "Gastric Mucus Effusion Elicited by Oral Copper Compounds: Potential Anti-Ulcer Activity", Experientia, 32, 1172-1173, (1976)
	C542	Raisz, L.G., "Estrogen and Bone: New Pieces to the Puzzle", Nature Medicine, 2, 1077-1078, (1996)
	C543	Raloff, "Tamoxifen Puts Cancer on Starvation Diet", Science News, 146, 292, (November 5, 1994)  Rauterberg, et al., "Collagens in Atherosclerotic Vessel Wall Lesions," Current Topics in Pathology, Vol. 87, pp.
	C544	Ray, P., et al., "Repression of interleukin-6 gene expression by 17beta-estradiol: Inhibition of the DNA-binding
	C545	activity of the transcription factors NF-IL6 and NF-6B by the estrogen receptor", FEBS Letters, 409, 79-85, (1997)
	C546	Razavi, M., "Unusual Forms of Coronary Artery Disease", Cleveland Clinic Consultations, 7, 25-46, (1975)
	C547	Recchia, F., et al., "Interferon-beta, Retinoids, and Tamoxifen in the Treatment of Metastatic Breast Cancer: A Phase II Study", Journal of Interferon and Cytokine Research, 15, 605-610, (1995)
	C548	Reckless, J., et al., "Tamoxifen Decreases Cholesterol Sevenfold and Abolishes Lipid Lesion Development in Apolipoprotein E Knockout Mice", Circulation, 95, 1542-1548, (1997)
	C549	Reid, et al., "Fragmentation of DNA in P388D <sub>1</sub> Macrophages Exposed to Oxidized Low-density Lipoprotein," FEBS Letters, Vol. 332, No. 3, pp. 218-220 (1993)
	C550	Reilly et al., "Antiproliferative effects of heparin on vascular smooth muscle cells are reversed by epidermal growth factor," J. Cell Physiol., 131 :t 49-157 (1987)
	C551	Reilly, C.F., "Rat Vascular Smooth Muscle Cells Immortalized with SV40 Large T Antigen Possess Defined Smooth Muscle Cell Characteristics Including Growth Inhibition by Heparin", Journal of Cellular Physiology, 142, 342-351, (1990)
	C552	Reis, G.J., et al., "Randomized Trial of Fish Oil for Prevention of Restenosis After Coronary Angioplasty", The Lancet, 177-181, (1989)
V	C553	Ribeiro, G., et al., "Adjuvant Tamoxifen for Male Breast Cancer (MBC)", Br. J. Cancer, 65, 252-254, (1992)

			of Application No. 10/603,115
TE	3	C554	Rieckmann, P., et al., "Tumor Necrosis Factor-a Messenger RNA Expression in Patients with Relapsing-Remitting Multiple Sclerosis is Associated with Disease Activity", Ann. Neurol, 27, 82-88, (1996)
<u> </u>		C555	Riessen et al., "Prospects for Site-Specific Delivery of Pharmacologic and Molecular Therapies", J. Amer. Collage of Cardiol., 23, 1234-1244 (Apr. 1994)
	_	CEEC	Riessen et al., "Regional Differences in the Distribution of the Proteoglycans Biglycan and Decorin in the
		C556	Extracellular Matrix of Atherosclerotic and Restenotic Human Coronary Ateries", Amer. J. Path 144, 962-974 (May 1994)
		C557	Roberts et al., "Type beta transforming growth factor: a bifunctional regulator of cellular growth," Proc. Natl. Acad. Sci., 82:119-123 (1985)
		C558	Robinson, J.R. (ed), "Sustained and Controlled Release Drug Delivery Systems," New York, Marcel Dekker (1978). Chapters 1-2, 4, and 7-9.
	*	C559	Roche Lexikon Medizin, Urban und Schwarzenberg, 1984, page 69 "Antibiotika", and page 515 "Fibrin" (including translation)
	*	C560	Rompp Chemie-Lexikon, 9th ed., pages 206-208, pages 1350 and 1351 (including translation)
	*	C561	Rompp, Chemie-Lexikon, 8th ed., 1987, page 2633 "Mitosehemmer" (including translation)
		C562	Ross, et al., "Chronic Inflammation, PDGF, TGF, and Smooth Muscle Proliferation, Abstracts from the 20 <sup>th</sup> Annual Meeting of the Keystone Symposia on Molecular Biology, Session on Molecular Mechanisms of Vascular Disease, J. Cell Biochem. S15C, Abstract No. G006, p. 96 (1991)
		C563	Ross, Russell, "The Pathogenesis of Atherosclerosis: A Perspective for the 1990s, Nature, Vol. 362, pp. 801-09 (1993)
		C564	Roubin, "Intracoronary Stenting of Canine Coronary Arteries After Percutaneous Coronary Angioplasty (PTCA)," Circulation 1986 Oct;74(Supp. II-458):1825 Abstract.
		C565	Rowinsky et al., "Taxol: Twenty years Later, the Story Unfolds," Journal of the National Cancer Institute, 1991, Vol 83 No. 24 pp 1778-1781
		C566	Rutqvist, L.E., et al., "Cardiac and Thromboembolic Morbidity Among Postmenopausal Women with Early-Stage Breast Cancer in a Randomized Trial of Adjuvant Tamoxifen", Journal of the National Cancer Institute, 85, 1398-1406, (1993)
		C567	Rutsch, et al., "Benestent-II Pilot Study: 6 months Follow Up of Phase 1" Abstract, Society of Cardiology, (1995)
		C568	Ruygrok and Serruys, "From Bench to Bedside, Intracoronary Stenting, From Concept to Custom," Circulation 1996; 94:882-890
		C569	Ryan et al., "Transforming growth factor-beta-dependent events in vascular remodeling following arterial injury," J Vase. Res., 40:37-46 (2003)
		C570	Saarto, T., et al., "Antiatherogenic Effects of Adjuvant Antiestrogens: A Randomized Trial Comparing the Effect of Tamoxifen and Toremifene on Plasma Lipid Levels in Postmenopausal Women with Node-Positive Breast Cancer", Journal of Clinical Oncology, 14, 429-433, (February 1996)
		C571	Sabatini et al., "RAFT1: a mammalian protein that binds to FK.BP12 in a rapamycin-dependent fashion and is homologous to yeast TORs", Cell, 78:35-43 (1994)
		C572	Sagitani, et al., "Microemulsion Systems with a Nonionic Cosurfant" J. Dispersion Science and Technology, 1 (2) 151-164 (1980)
		C573	Saito, H., et al., "Influence of Maternal Drug Metabolism on the Fetal Toxicity Induced by Acetylsalicylic Acid", The Journal of Toxicological Sciences, 7, 177-184, (1982)
		C574	Sanders, et al., "Controlled Release of a Luteinizing Hormone-Releasing Hormone Analogue from Poly(d,I-
		C575	lactide-co-glycolide) Microspheres," Journal of Pharmaceutical Sciences, Vol. 73, No. 9, pp. 1294-1297 (1984)  Sanderson et al., "Antibody-Coated Microspheres for Drug Delivery to Prevent Restenosis", Circulation, 90,  I 508, Abstract No. 2734 (October 1994)
		C576	Sargent, L.M., et al., "Induction of Hepatic Aneuploidy in Vivo by Tamoxifen, Toremifene and Idoxifene in Female Sprague-Dawley Rats", Carcinogenesis, 17, 1051-1056, (1996)
		C577	Schatz et al., "Balloon-expandable Intra-coronary Stents In The Adult Dog," Circulation 1987 Aug; 76(2):450-457.
		C578	Schatz, "A View of Vascular Stents", Circulation, 79 445-457 (1989)
		C579	Schatz, et al., "Balloon Expandable Intracoronary Stents In Dogs," Circulation 1986 Oct;74(Supp. II-458): 1824 Abstract,
		C580	Schatz, et al., "Clinical Experience with the Palmaz-Schatz Stent: Initial Results of A Multicenter Study," Circulation 1991 Jan;83(1): 148-161.
		C581	Schatz, R.A. Introduction to Intravascular Stents, Cardiology Clinics 1988 Aug;6(3):357-72.
		C582	Schlaak, J.F., et al., "Different Cytokine Profiles in the Synovial Fluid of Patients with Osteoarthritis, Rheumatoid Arthritis and Seronegative Spondylarthropathies", Clinical and Experimental Rheumatology, 14, 155-162, (1996)
		C583	Schlingemann, et al., Expression of the High Molecular Weight Melanoma-Associated Antigen by Pericytes During Angiogenesis in Tumors and in Healing Wounds," Amer. J. Pathology, Vol. 136, No. 6, pp. 1393-1405 (1990)
		C584	Schmidt, E.B., et al., "Long-Term Supplementation with n-3 Fatty Acids, II: Effect on Neutrophil and Monocyte Chemotaxis", Scand. J. Clin. Lab. Invest., 52, 229-236, (1992)
1/		C585	Schneiderman, et al., "Increased Type I Plasminogen Activator Inhibitor Gene Expression in Atherosclerotic Human Arteries," PNAS (USA), Vol. 89, pp. 6998-7002 (1992)

		of Application No. 10/603,115
TB	C586	Schoenemanne, et al., "The Differential Diagnoses of Spontaneous Pneumothrax and Pulmonary Lymphangioleimyomatosis Clinical Picture Diagnoses and Theory.", Chiraq, 61, 301-303 (1990); reported in
	C587	Biosis, 90, 432367 (1990), English abstract only  Schulick et al, "Overexpression of transforming growth factor beta1 in arterial endothelium causes hyperplasia,
		apoptosis, and cartilaginous metaplasia," PNAS 95:6983-6988 (1998)
	C588	Schwartz, C.J., et al., "The Pathogenesis of Atherosclerosis: An Overview", Clin. Cardiol., 14, I-1I-16, (1991)
	C589	Schwartz, et al., "Maintenance of Integrity in Aortic Endothelium," Fed. Proc., Vol. 39, No. 9, pp. 2618-25 (1980)
	C590	Schwartz, et al., "Restenosis After Balloon Angioplasty - A Practical Proliferative Model in Porcine Coronary Arteries, Circulation, Vol. 82, No. 6, pp. 2190-2200 (1990)
	C591	Schwartz, et al., "The Restenosis Paradigm Revisited: An Alternative Proposal for Cellular Mechanisms," JACC, Vol. 20, No. 5, pp. 1284-93 (1992)
	C592	Schwartz, G.G., et al., "Pathophysiology of Chronic Stable Angina", In: Atherosclerosis and Coronary Artery Disease, V. Fuster, et al., (eds.), Lippencott-Raven Publishers, Philadelphia, pp. 1386-1400, (1996)
	C593	Sedlacek, S. "Estrogenic Properties of Tamoxifen on Serum Lipids in Postmenopausal Women with Breast Cancer (BCA)", Breast Cancer Research and Treatment, 14, Abstract No. 82, 153, (1989)
	C594	Sehgal et al., "Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization." J. Antibiot., 28:727-32 (1975)
	C595	Sehgal, "Sirolimus: its discovery, biological properties, and mechanism of action." Transplant. Proc., 35(3 Suppl):7S-148 (2003)
	C596	Serruys et al., "The new angiotensin converting enzyme inhibitor cilazapril does not prevent restenosis after coronary angioplasty: the results of the MERCATOR trial," JACC 19:258A, Abstract 783-2 (1992)
	C597	Serruys, et al., "A Comparison of Balloon-Expendable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease", The New England Journal of Medicine, 331, 489-495 (August, 1994)
	C598	Serruys, P.W., et al., "Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries Early Outcome of the Benestent-II Pilot Study", Circulation, 93, 412-422, (Feb. 1996)
	C599	Shanahan and Weissberg, "Smooth muscle cell heterogeneity: patterns of gene expression in vascular smooth muscle cells in vitro and in vivo," Arterioscler. Thromb. Vase. Biol., 18(2):333-338 (1998)
	C600	Shanahan, C.M., et al., "High Expression of Genes for Calcification-regulating Proteins in Human Atherosclerotic Plaques", Journal of Clinical Investigation, 93, 2393-2402, (June, 1994)
	C601	Shananhan, et al., "Isolation of Gene Markers of Differentiated and Proliferating Vascular Smooth Muscle Cells," Circulation Research, Vol. 73, No. 1 (1993)
	C602	Shapiro, L.M., "Echocardographic Features of Impaired Ventricular Function in Diabetes Mellitus", British Heart Journal, 47, 439-444, (1982)
	C603	Shemon, et al., "Tamoxifen Decreases Lipoprotein(a) in Patients with Breast Cancer.", Metabolism, 43, 531-532, (May 1994)
	C604	Shewmon, et al., "Tamoxifen and Estrogen Lower Circulating Lipoprotein(a) Concentration in Healthy Postmenopausal Women", Arteriosclerosis and Thrombosis, 14, 1589-1593, (1994)
	C605	Shewmon, et al., "Tamoxifen Lowers Lp(a) in Males with Heart Disease," Supplement I Cir., Vol. 86, No. 4, p. 1345 (1992)
	C606	Shimaoka, I., et al., "Purification of a Copper Binding Peptide from the Mushroom Grifola Frondosa and Its Effect on Copper Absorption", J. Nutr. Biochem., 4, 33-38, (1993)
	C607	Shoji, et al., "Enhancement of Anti-Inflammatory Effects of Biphenylylacetic Acid by its Incorporation into Lipid Microspheres," J. Pharm. Pharmacol. 38:118-121 (1985)
	C608	(6666):489-92 (1998)
	C609	Siebenlist, U., et al., "Structure, Regulation and Function of NF-kB", Annu. Rev. Cell. Biol., 10, 405-455, (1994)
	C610	Coroinary Stents. Springer-Verlag (1992)
	C611	Sigwart, Ulrich, "The Self Expanding Mesh Stent" Textbook of Interventional Cardiology, (Eric J. Topol, ed) 1990, Chapter 29, pp 605-622
	* C612	Silber, S. "Drug-eluting stents: aktueller Stand", internet article on http://sigmund-silber.com/deutsch/varia/var-2003/03-09-5-Silber-Chemnitz.pdf of August 6, 2003
	C613	Simpson, J.B., et al., "Percutaneous Coronary Atherectomy", Circulation, 978, 61st Scientific Session, Abstract No. 0326, p. II-82, (Oct., 1988)
	C614	Singh, et al., "Phylogenetic Analysis of Platelet-derived Growth Factor by Radio-Receptor Assay," The Journal of Cell Biology, Vol. 95, pp. 667-671 (1982)
	C615	Sismondi, et al., "Metabolic Effects of Tamoxifen in Postmenopause.", Anticancer Res., 14, 2237-2244, (1994)
	C616	Snow, et al., "Heparin Modulates the Composition of the Extracellular Matrix Domain Surrounding Arterial Smooth Muscle Cells," American J. of Pathology, Vol. 137, No. 2 (1990)
	C617	Soderberg, L.S., et al., "Copper (II) (3,5-Diisopropylsalicylate) sub2 Accelerates Recovery of B and T Cell Reactivity Following Irradiation", Scand J. Immunol., 26, 495-502, (1987)
	C618	Soderberg, L.S., et al., "Copper (II) sub2(3, 5-diisopropylsalicylate) sub4 Stimulates Hemopoiesis in Normal and Irradiated Mice", Exp. Hematol., 18, 577-580, (1988)
<b>V</b>	C619	Soderberg, L.S., et al., "Postirradiation Treatment with Copper (II) sub2 (3,5-diisopropylsalicylate) sub4 Enhances

TB			Radiation Recovery and Hemopoietic Regeneration", Exp. Hematol., 18, 801-805, (1990)
ı	C6	20	Soderberg, L.S., et al., "Radiation Recovery Agents", DN & P, 3, 600-605, (1990)
	C6	521	Sollott, S.J., et al., "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation after Angioplasty in the Rat", The Journal of Clinical Investigation, 95, 1869-1876, (Apr., 1995)
C622			Song "Dexamethasone-nanoparticles for intra-arterial localization in restenosis in rats," Preed. Intern .Symp. Control. Rel. Mater., 22, 444-445 (1995)
	C6	523	Song, J., et al., "Tamoxifen (Estrogen Antagonist) Inhibits Voltage-Gated Calcium Current and Contractility in Vascular Smooth Muscle from Rats", The Journal of Pharmacology and Experimental Therapeutics, 227, 1444-1453, (1996)
	C6	524	Sorenson, J.R., "Copper Complexes Offer a Physiological Approach to Treatment of Chronic Disease", Progress in Medicinal Chemistry, 26, 437-568, (1989)
	Ce	525	Sorenson, J.R., "Essential Metalloelement Metabolism and Radiation Protection and Recovery", Radiation Research, 132, 19-29, (1992)
	Cé	526	Sorenson, J.R., "Pharmacological Activities of Copper Compounds", In: Handbook of Metal-Ligand Interactions in Biological Fluids Bioinorganic Medicince, vol. 2, Berton, G., (ed.), Marcel Dekker, Inc., New York, 1128-1139, (1995)
	Cé	527	Sorenson, J.R., "Radiation Protection and Radiation Recovery with Essential Metalloelement Chelate", P.S.E.B.M., 210, 191-204, (1995)
	Cé	528	Sorenson, J.R., "The Ulcerogenic Potential of Copper Aspirinate Seems to be More Imaginary than Real", Journa of Pharmaceutical Sciences, 73, Open Forum, 1875-1878, (1984)
	Cé	529	Sorenson, J.R., et al., "Antieoplastic Activities of Some Copper Salicylates", In: Trace Substances in Environmental Health, vol. XVI, Hemphill, D.D., (ed.), University of Missouri, Columbia, 362-369, (1982)
	Cé	530	Sorenson, J.R., et al., "Bis (3, 5-diisopropylsalicylato) copper (II), a Potent Radioprotectant with Superoxide Dismutase Mimetic Activity", J. Med. Chem., 27, 1747-1749, (1984)
	Cé	531	Sorenson, J.R., et al., "Copper Complexes as 'Radiation Recovery' Agents", Chemistry in Britain, 25, 169-171, (1989)
		532	Sorenson, J.R., et al., "Copper-, Iron-, Manganese- and zinc-3, 5-diisopropylsalicylate Complexes Increase Survival of Gamma-Irradiated Mice", Eur. J. Med. Chem., 28, 221-229, (1993)
		533	Sousa et al., "Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up," Circulation, 104:2007-i 1 (2001) (CYP228071-228075)
		634	Sousa et al., "Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus- eluting stents in human coronary arteries," Circulation. 107(3):381-3 (2003) (BSX 024170-024172)
		635 636	Sousa, J.E. et al., "New Frontiers in Cardiology Drug-Eluting Stens: Part I", Circulation, 2003, 107:2274-2279, Southgate and Newby, "Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile states."
	_	637	is inhibited by 8-Br-cAMP but not 8-Br-cGMP," Atherosclerosis, 82:113-123 (1990)  Speir et al., "Potential Role of Human Cytomegalorvirus and p53 Interaction in Coronary Restenosis", Science,
	C	638	265, 391-394 (1994) Srivastava, K.C., "Effects of Dietary Fatty Acids, Prostaglandins and Related Compounds on the Role of Platelet
	C	639	in Thrombosis", Biochem. Exp. Biol., 16, 317-338, (1980)  Standley, P.R., et al., "Tamoxifen (an Antiestrogen) Reduces K Positive- and Agonist-Induced Vascular
	C	640	Contractility in Rat Resistance Vessels", Abstract No. 159 (Source and Date Unavailable)  Steele, P.M. et al., "Balloon Angioplasty Nature History of the Pathophysiological Response to Injury in a Pig
	C	641	Model", Circulation Research, 57 105-112 (1985)  Stevenson, F., et al., "Idiotypic DNA Vaccines against B-cell Lymphoma", Immunological Reviews, 145, 221-
	C	642	228, (1995) Stork, G., et al., "Total Synthesis of Cytochalasin B", Journal of the American Chemical Society, 100, 7775-777 (1978)
	C	643	Stouffer, et al., "TGF beta Has a Biphasic, Concentration Dependant Effect on EFG and PDGR-BB Induced Smooth Muscle Cell Proliferation, Inflammation, Growth Regulatory Molecules and Atherosclerosis.", J. Cellula Biochem, Supplement 18A, Abstract No. A321, 288, (1994)
	C	644	Strepetti, A.V., et al., "Formation of Myointimal Hyperplasia and Cytokine Production in Experimental Vein Grafts", Surgery, 123(4), 461-469, (1998)
	C	645	Streuli, et al., "Extracellular Matrix Regulators Expression of the TGF-β1 Gene," The J. of Cell Biol. Vol. 120, No. 1, pp. 253-260 (1993)
	C	646	Suckling, "Atherosclerosis Patents: Clues to the Next Drug Generation", Bio/Tech, 12 1379-1380 (December 1994)
	C	647	Suckling, Keith E., "Emerging Strategies for the Treatment of Atherosclerosis as Seen from the Patent Literature Biochem. Society Transactions, Vol. 21, pp. 660-662 (1993)
	C	648	Sudo, K., et al., "Antiestrogen-Binding Sites Distinct from the Estrogen Receptor: Subcellular Localization, Ligand Specificity, and Distribution in Tissues of the Rat", Endocrinology, 112, 425-434, (1983)
	C	649	Swain, "Blazing new paths for product introductions," Medical Device & Diagnostic Industry, Sept. 2003, p. 68-81
$\Psi$	C	650	Szekanecz, Z., et al., "Increased Synovial Expression of Transforming Growth Factor (TGF) -B Receptor Endog and TGF- B1 in Rheumatoid Arthritis: Possible Interaction in the Pathogenesis of the Disease", Clinical Immunology and Immunopathology, 76, 187-194, (August 1995)

			of Application No. 10/603,115
TB		C651	Tabas et al., "the Actin Cytoskeleton in Important for the Stimulation of Cholesterol Esterification by Atherogenic
	-		Lipoprotiens in Macrophages" J. Biol. Chem., 269, 22547-22556 (Sept. 9 1994)
		C652	Takashima, K. et al., "The Hypocholesterolemic Action of TA-7552 and its Effects on Cholesterol Metabolism in
	├		the Rat", Atherosclerosis, 107, 247-257, (1994)  Tanaka et al., "Ialpha 25 (OH) 303 Exerts Cytostatic effects on Murine Osteosarcoma Cells and Enhance
		C653	Cytocidal Effects on Anticancer Drugs" Clinical Orthopaedics and related Research no. 247 1989 pgs. 290-296
		0(54	Tanaka et al., "Prominent Inhibitory Effects of Tranilast on Migration and Proliferation of and Collagen Synthesis
		C654	by Vascular Smooth Muscle Cells" Atherosclerosis, 107, 179-185 (1994)
	$\vdash$	C655	Tanenbaum, S.W., "Microbiological, Preparative and Analytical Aspects of Cytochalasin Production", In:
1		0055	Cytochalasins Biochemical and Cell Biological Aspects, Tanenbaum, S.W., (ed.), Elsevier/North-Holland
			Biomedical Press, 2-14, (1978)
	C6		Tang et al., "Regression of collagen-induced arthritis with taxol, a microtubule stabilizer". Arthritis and
	L		Rheumatism, 36 (9) Suppl.:S45, 1993
j		C657	Tawashi, R., "The dissolution rates of crystalline drugs", J. Mond. Pharm, 4,11,1968, pp 371-379
		C658	Teirstein (ed.), "Coronary Stents: pros and cons," Coronary Artery Disease, 5:561-600 (1994).
		C659	Tessari et al., "Antiproliferative activity of unfractioned heparin on a human smooth muscle cell line, Pharmacol."
	l	0037	Res., 21:145-6 (1989)
		C660	Testart, J., et al., "The Action of Anti-Inflammatory Drugs to the Fertility of Female Rats with Intrauterine
			Contraceptive Devices", J. Reprod. Fert., 63, 257-261, (1981)
		C661	Thompson, J.T., et al., "Comparison of Recombinant Transforming Growth Factor-beta -2 and Placebo as an
	<u> </u>	ļ	adjunctive Agent for Macular Hole Surgery", Ophthalmology, 15(4), 700-706, (1998)
	i	C662	Thompson, N.L., et al., "Expression of Transforming Growth Factor-B1 in Specific Cells and Tissue of Adult and Neonatal Mice", Journal of Cell Biology, 108, 661-669, (1989)
		CCC	Tice, et al., "Biodegradable controlled-release parental systems" Pharmaceutical Technology, 26-35 (1984)
	<u> </u>	C663	Topol, E. et al., "Frontiers in Interventional Cardiology" Circulation, 1998, 98:1802-1820,
	<u> </u>	C664	
	*	C665	Topol, Eric J., "The Restenosis "Antitheory", Mayo Clinic Proc. Vol. 68, pp. 88-90 (1993)
		C666	Treasure, C.B., et al., "Hypertension and Left Ventricular Hypertrophy Are Associated With Impaired
<del></del>	├		Endothelium-Mediated Relaxation in Human Coronary Resistance Vessels", Circulation, 87, 86-93, (1993)  Treiber, A., et al., "Chemical and Biological Oxidation of Thiophene: Preparation and Complete Characterization
- 1		C667	of Tiophene S-Oxide Dimers and Evidence for Thiophene S-Oxide as an Intermediate in Thiophene Metabolism in
- 1			vivo and In Vitro", J. Am. Chem. Soc., 119, 1565-1571, (1997)
	<b></b>	C668	Tucker et al., "Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor,"
			Science, 226:705-707 (1984)
		C669	Ulman, et al., "Drug Permeability of Modified Silicone Polymers," Journal of Controlled Release 1989; 10:276-
			281
		C670	Van Der Giessen, et al., "Self-expandable Mesh Stents: an Experimental Study Comparing Polymer Coated and
			Uncoated Wallstent Stents in the Coronary Circulation of Pigs" "Circulation 82:III-542 (1990)
		C671	Van Sickle, W.A., et al., "An Alternative Mechanism for the Inhibition of Cholesterol Biosyntesis in HepG2 Cells
ı			by N- [(1,5,9) -Trimethyldecyl] -4alpha, 10-dimethyl 8-aza-trans-decal-3beta-ol (MDL 28, 815)", The Journal of
	<b> </b>		Pharmacology and Experimental Therapeutics, 267, 243-1249, (1993)
		C672	Vanhoutte, P.M., "Hypercholesterolemia, Atherosclerosis And Release Of Endothelium-Derived Relaxing Factor By Aggregating Platelets," European Heart J. Vol. 12, Supplement E. pp. 25-32 (1991)
	$\vdash$	0.55	Vargas, et al., "Oestradiol Inhibits Smooth Muscle Cell Proliferation of Pig Coronary Artery," Br. J. Pharmacol.,
		C673	Vol. 109, pp. 612-617 (1993)
	_	C674	Vawter, M.P., et al., "TGF B1 and TGF B2 Concentrations are Elevated in Parkinson's Disease in Ventricular
L	L		Cerebrospinal Fluid", Experimental Neurology, 141, 313-332, (1996)
		C675	Vidensek N., et al., "Taxol Content in Bark, Wood, Root, Leaf, Twig, and Seedling from Several Taxus Species",
	<u> </u>	<u> </u>	Journal of Natural Products, 53, 1609-1610, (Nov./Dec., 1990)
	l	C676	Vijayagopal, et al., "Human Monocyte-Derived Macrophages Bind Low-Density-Lipoprotein-Proteoglycan
	ľ		Complexes by a Receptor Different from the Low-Density-Lipoprotein Receptor," Biochem. J., Vol. 289, pp. 837-
	$\vdash$		844 (1993) (GB)   Vijayagopal, et al., "Lipoprotein-Proteoglycan Complexes Induce Continued Cholesteryl Ester Accumulation in
i	ĺ	C677	Foam Cells from Rabbit Atherosclerotic Lesions," J. Clin. Invest. Vol. 91, pp. 1011-18 (1993)
	┢─	C678	Voigt, R., Lehbuch der pharmazeutischen Technologie, 5th. edition VEB Verlag Volk und Gesundheit Berlin,
	1	C0/8	1984, p 689
		C679	Voisard, et al., "The In-Vitro Effect of Antineoplastic Agents on Proliferative Activity and Cytoskeletal
	ĺ		Components of Plaque-derived Smooth-muscle Cells from Human Coronary Arteries," Coronary Artery Disease,
	L_	<u> </u>	4:935-942 (1993)
		C680	Voisard, R., et al., "Search for new strategies for prevention of restenosis after angioplasty: the effect of cytostatic
	Ì		drugs on cell migration of re-stenosing human plaques cells in vitro". Vasa Suppl. 1992; 35: 132-3 [Article in
<del>-\ /</del>	<del> </del> -	000	German    Von Schacky, C., et al., "Long-Term Effects of Dietary Marine omega-3 Fatty Acids upon Plasma and Cellular
₩.	l	C681	Lipids, Platelet Function, and Eicosanoid Formation in Humans", J. Clin. Invest., 76, 1626-1631, (1985)
	Щ.	I	Large and American and an endounter of mander in training 3.5. Citil integr., 70, 1020-1031, (1703)

		of Application No. 10/603,115			
TB	C682	Wakefield, et al., "Latent Transforming Growth Factor β from Human Platelets: A High Molecular Weight Complex Containing Precursor Sequences," The Journal of Biological Chemistry, Vol. 263, No. 16, pp. 7646-7654 (1988)			
	<del></del>				
	C683	Wakefield, et al., "Recombinant Latent Transforming Growth Factor I Has a Longer Plasma Half-Life in Rats than Active Transforming Growth Factor, I, and a Different Tissue Distribution," The Journal of Clinical Investigation, Inc., Vol. 86, pp. 1976-1984 (1990)			
C684		Waksman, R., et al., "Intracoronary Radiation Before Stent Implantation Inhibits Neointima Formation in Stented Porcine Coronary Arteries", Circulation, 92, 1383-1386, (1995)			
C685		Wallace, et al., "Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications," RADIOLOGY 1986 Feb; 158(2):309-12.			
	C686	Wallace, J.M., et al., "Dietary Fish Oil Supplementation Alter Leukocyte Function and Cytokine Production in Healthy Women", Arteriosclerosis, Thrombosis and Vascular Biology, 15, 185-189, (1995)			
C687		Waller et al., "Crackers, Breakers, Stretchers, Drillers, Scrappers, Shavers, Burners, Welders and Melters: The Future Treatment of Atherosclerotic Coronary Artery Disease?" A Clinical-Morphologic Assessment," JACC 13:969-87 (1989)			
	C688	Waller et al., "Differential effects of modern immunosuppressive agents on the development of intimal hyperplasia," Transpl. Int. 17:9-14 (2004)			
	C689	Waller et al., "Mycophenolate mofetil inhibits intimal hyperplasia and attenuates the expression of genes favouring smooth muscle cell proliferation and migration," Transplant Proc. 37(1): 164-6 (2005).			
	C690	Waller, B.F. X.L., et al., "Atherosclerotic and Nonatherosclerotic Coronary Artery Factors in Acute Myocardial Infarction", In: Acute Myocardial Infarction, Pepine, C.J., (ed.), F.A. Davis Company, Philadelphia, 29-104, (1989)			
	C691	Walternberger, "Modulation of growth factor action: implications for the treatment of cardiovascular diseases," Circulation, 96:4083-4094 (1997)			
	C692	Wang, X.L., et al., "Circulating Transforming Growth Factor Betal and Coronary Artery Disease", Cardiovascular Research, 34, 404-410, (1997)			
	C693	Ward et al., "Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries," Atherosclerosis, 137:267-			
		Ward et al., "Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting," Arterioscler. Thromb. Vasc. Biol. 22:940-948 (2002);			
		Watson, et al., "TGF-B1 and 25-Hydroxcholesterol Stimulate Osteoblast-Like Vascular Cells to Calcify", J. Clin. Invest., 93, 2106-2113, (May 1994)			
	C696	Wei, C.M. et al., "Binding of Trichodermin to Mammalian Ribosomes and Its Inhibition by Other 12, 13- Epoxytrichotheces", Molecular & Cellular Biochemistry, 3, 215-219, (May 30, 1974)			
	C697	Weissberg, et al., "Approaches to the development of selective inhibitors of vascular smooth muscle cell proliferation," Cardiovascular Res., Vol. 27, pp. 1191-98 (1993)			
	C698	Weissberg, et al., "The Endothelin Peptides ET-1, ET-2, ET-3 and Sarafotoxin S6b are Comitogenic with Platelet- Derived Growth Factor for Vascular Smooth Muscle Cells," Atherosclerosis, Vol. 85, pp. 257-262 (1990)			
	C699	Weissberg, et al., Effects of TGFB on Vascular Smooth Muscle Cell Growth, Growth Factors and the Cardiovascular System, (Cummins, P. ed), Kluwer Academic Publishers, p. 189-205 (1993)			
		Weissberg, P.L., et al., "Is Vascular Smooth Muscle Cell Proliferation Beneficial?", Lancet, 347, 305-307, (Feb. 3 1996)			
	C701	West, G.B., "Comments on 'The Ulcerogenic Potential of Copper Aspirinate Seems to be More Imaginary than Real'", Journal of Pharmaceutical Sciences, 74, Open Forum, 700, (1985)			
	C702	West, G.B., "Testing for Drugs Inhibiting the Formation of Gastric Ulcers", Journal of Pharmacological Methods, 8, 33-37, (1982)			
	C703	Wickremesinhe, E.R., et al., "Taxus Callus Cultures: Initiation, Growth, Optimization, Characterization and Taxol Production", Plan Cell, Tissue and Organ Culture, 35, 181-193, (1993)			
	C704	Wickremesinhe, E.R., et al., "Taxus Cell Suspension Cultures: Optimizing Growth and Production of Taxol", J. Plant Physiol., 144, 183-188, (1994)			
	C705	Wight, et al., "Proteoglycans Structure and Function," Cell Biol. of Extracellular Matrix, Second Edition, edited by Elizabeth D. Hay, Plenum Press, New York Chapter 2, pp. 45-78 (1991)			
	C706	Wight, et al., "The Role of Proteoglycans in Cell Adhesion, Migration and Proliferation," Current Opinion in Cell Biol. Vol. 4, pp. 793-801 (1992)			
	C707	Wight, Thomas N., "Cell Biology of Arterial Proteoglycans," Arteriosclerosis, Vol. 9, No. 1., pp. 1-20 (1989)  Wilensky, et al., "Direct Intraarterial Wall Injection of Microparticles via a Catheter: A Potential Drug Delivery			
		Strategy Following Angioplasty," American Heart Journal, Vol. 122, No. 4, pp. 1136-1140 (1991)			
		Wilensky, et al., "Regional and Arterial Localization of Radioactive Microparticles after Local Delivery by Unsupported Porous Balloon Catheters", American Heart Jounal, 129, 852-859 (May 1995)			
	C710	Wilensky, R.L., et al., "A Prospective, Randomized, Double-Blind, Dose-Escalation Study Evaluating the Safety and Tolerability of Cytochalasin B to Reduce Vascular Remodeling Following Percutaneous Transluminal Coronary Angioplasty", Abstract, 46 <sup>th</sup> Annual Scientific Session of the American College of Cardiology, 1 p., (1997)			
/	C711	Williams, J.K., et al., "The Estrogen Receptor Agonist/Antagonist Tamoxifen Inhibits Progression of Coronary Artery Atherosclerosis in Monkeys", Circulation, 92, November 1995 AHA Meeting, (October 15, 1995)			
	TB	C683 C684 C685 C686 C687 C688 C689 C690 C690 C691 C692 C693 C694 C695 C696 C697 C698 C699 C700 C701 C702 C703 C704 C705 C706 C707 C708 C709			

			of Application No. 10/603,115
TB	ŀ	C712	Willson, T.M., et al., "Dissection of the Molecular Mechanism of Action of GW5638, a Novel Estrogen Receptor
	_		Ligand, Provides Insights into the Role of Estrogen Receptor in Bone", Endocrinology, 138(9), (September 1997)
1		C713	Winslow, R., "Going for the Flow", The Wall Street Journal, (Oct. 23,1995)
		C714	Winternitz, C.I. et al., "Development of a Polymetric Surgical Paste Formulation for Taxol", Pharmaceutical
		0,	Research, 13 368-375 (1996)
		C715	Wiseman, H., "Tamoxifen as an Antioxidant and Cardioprotectant", Biochem. Soc. Symp., 61, 209-219, (1995)
	+	6716	Wiseman, L.R., et al., "Toremifene A Review of its Pharmacological Properties and Clinical Efficacy in the
İ	1	C716	Management of Advanced Breast Cancer", Drugs, 54, 141-160, (July 1997)
	+	C717	Witherup, K.M., et al., "Taxus Spp. Needles Contain Amounts of Taxol Comparable to the Bark of Taxus
	1	6/1/	brevifolia: Analysis and Isolation", Journal of Natural Products, 53, 1249-1255, (Sep./Oct., 1990)
		C718	Wolf, Y.G., et al., "Antibodies Against Transforming Growth Factor Betal Suppress Intimal Hyperplasia in a Rat
	-		Model", J. Clin. Invest., 93, 1172-1178, (Mar. 1994)
		C719	Wolinsky, et al., "Use of a Perforated Balloon Catheter to Deliver Concentrated Heparin Into the Wall of the Normal Canine Artery, JACC, Vol. 15, No. 2, pp. 475-81 (1990)
		C720	Wrana, et al., "Mechanism of Activation of the TGF-B Receptor", Nature, 370 341-347, (August 4, 1994)
	<u> </u>		
		C721	Wright et al., "Cytoclasin Inhibition of Slow Tension Increase in Rat Aortic Rings", Am. J. Physion., 267 H1437-H1446 (1994)
		C722	Wright et al., "Percutaneous Endovascular Stents: An Experimental Study," Radiology 1984 Nov;153(P):206 Abs
	+-	C722	593.   Wright et al., "Percutaneous Endovascular Stents: An Experimental Evaluation," Radiology 1985;1:69-72.
	<del> </del>	C723	
		C724	Wu et al., "Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cylokine production and lymphoproliferation," Transplant. Porc., 23:238-240 (1991)
		C725	Wu et al., "The inhibitory mechanism of YC-1, a benzyl indazole, on smooth muscel cell proliferation: an in vitro
			and in vivo study," J. Pharmacol. Sci. 94:252-60 (2004)
		C726	Yamamoto et al., "Ribozyme oligonucleotides against transforming growth facotr-beta inhibited neointimal
			formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular
	+	ļ	disease," Circulation, 102(11):1308-14 (2000)
ł		C727	Yang, N., et al., "Developing Particle-mediated Gene-transfer Technology for Research Into Gene Therapy of
<del></del>	+	0700	Cancer", Molecular Medicine Today, 476-481, (1996)  Yang, N.N., et al., "Estrogen Receptor: One Transcription Factor, Two Genomic Pathways", Calcified Tissue
		C728	Intl., 54, 342, (1994)
		C729	Yang, N.N., et al., "Identification of an Estrogen Response Element Activated by Metabolites of 17Beta-Estradiol
- 1		(72)	and Raloxifene", Science, 273, 1222-1225, (Oct. 30, 1996)
		C730	Young H., et al., "Pharmacokinetics and Biodistribution of Radiolabelled Idoxifene: Prospects for the Use of PET
		ļ	in the Evaluation of a Novel Antioestrogen for Cancer Therapy", Nucl. Med. Biol., 22, 405-411, (May 1995)
l		C731	Zhang, L. et al., "MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in
	-	ļ	ovariectomized and tamoxifen-treated nude mice", Oncogen, 15, 2093-2108, (1997)
		C732	Ziegler, J. "Raloxifene, Retinoids, and Lavender: AMe Too@ Tamoxifen Alternatives Under Study", Journal of the National Cancer Institute, 88, 1100-1102, (1996)
		C733	Zohlnhofer et al., "Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and
			inflammatory properties," Mol. Pharmacol. 65:880-889 (2004)
- 1		C734	Zuckerman, et al., "Cytokine Regulation of Macrophage apo E Secretion: Opposing Effects of GM-CSF and TGF-
			β," Atherosclerosis, Vol. 96, pp. 203-214 (1992)
		C735	Zuckerman, et al., "Exogenous Glucocorticoids Increase Macrophage Secretion of E by Cholesterol-Independent Pathways," Atherosclerosis, Vol. 103, pp. 43-54 (1993)
	*	C736	BSC's Answering Brief in Opposition to Cordis' Motion for Summary Judgment Barring BSC from Asserting
	4_		Equivalents for Certain Limitations of the '536 Patent
	*	C737	BSC's Reply Brief in Further Support of its Motion for Summary Judgment that Claims 6 and 8 of the '536 Patent are
	*	0777	Not Anticipated by the Asserted Prior Art  BSC's Reply Brief in Further Support of its Motion for Summary Judgment that the Cypher Stent Infringes Claims 6 and
1	•	C738	8 of U.S. Patent No. 6,120,536
	*	C739	Cordis' Answering Brief in Opposition to BSC's Motion for Summary Judgment that Claims 6 and 8 of the Ding '536
			Patent are Not Anticipated by the Asserted Prior Art
- 1	*	C740	Cordis' Answering Brief in Opposition to BSC's Motion for Summary Judgment that the Cypher Stent Infringes Claims
	+	C741	6 and 8 of U.S. Patent No. 6,120,536  Cordis' Answering Markman Brief on the Construction of Terms in the Ding '536 Patent
	+	C741	Plaintiffs Boston Scientific Scimed, Inc. and Boston Scientific Corporation's Opening Claim Construction Brief
	*	C742	
		C743	Plaintiffs Boston Scientific Scimed, Inc. and Boston Scientific Corporation's Rebuttal Claim Construction Brief
J	*	C744	Plaintiffs BSC's Memorandum in Support of its Motion for Summary Judgment that Claims 6 and 8 of the '536 Patent
	+	C745	are Not Anticipated by the Asserted Prior Art  Plaintiffs BSC's Memorandum in Support of its Motion for Summary Judgment that the Cypher Stent Infringes Claims 6
		C/43	and 8 of U.S. Patent No. 6,120,536 Patent
V	*	C746	Redacted Public Version: Cordis' Opening Markman Brief on the Construction of Terms in the Ding '536 Patent
<del>-</del>			

TB	*	C747	C747 Redacted Public Version: Opening Brief in Support of Cordis' Motion for Summary Judgment Barring BSC from Asserting Equivalents for Certain Limitations of the Ding Patent				
TB * C748 Reply Brief in Support of Cordis' Motion for Summary Judgment Barring BSC from Asserting Equivalen Certain Limitations of the Ding Patent							
		C749	"Coronary Artery Disease: Restenosis and Reocclusion After Surgical and Nonsurgical Interventions, Part 1", Durg and Market Development, 5, 121-129 (Sept. 26, 1994)				

	Durg and Market Development, 5, 1	21-129 (Sept. 26, 1994)	
EXAMINER	06/26/2006	DATE CONSIDERED	/Thomas Barrett/
	if reference considered, whether or not citation is in opy of this form with next communication to applica		th citation if not in conformance and not